3. NON-AIDS DEFINING CANCER MORTALITY IN PEOPLE LIVING WITH HIV

Marta Rava1,2, Félix Gutierrez2,3, José A Pérez-Molina2,4, Inés Suarez-García2,5, Francisco Jesús Vera Méndez6, Fernando Baigorria Feltrin7, Mar Masiá2,8, Juan Macías2,9, Gemma Navarro10, Santiago Moreno2,11, Inma Jarrín1,2, Cohorte Coris12

1 Instituto de Salud Carlos III, Madrid, Spain. 2 Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 3Hospital General Universitario de Elche & Universidad Miguel Hernández, Alicante, Spain. 4Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. 5Hospital Universitario Infanta Sofía, Madrid, Spain. 6Hospital General Universitario Santa Lucía, Cartagena, Spain. 7 Complexo Hospitalario de Navarra, Pamplona, Spain. 8Hospital General Universitario de Elche, Alicante, Spain. 9Hospital Universitario Virgen de Valme, Sevilla, Spain. 10Parc Taulí Hospital Universitari, Barcelona, Spain. 11Hospital Ramón y Cajal, Madrid, Spain. 12CIBER, Instituto de Salud Carlos III, Madrid, Spain.

Introduction: Non-AIDS-defining cancers (NADC) represent one of the leading causes of death in people living with HIV (PLWH), with higher rates than in the general population. Both traditional and HIV-related risk factors play a role in NADC mortality and characterizing them may suggest areas of intervention.

Objectives: Our aim was to evaluate rate and prognostic factors of NADC mortality among PLWH from the CoRIS cohort.

Methods: We included antiretroviral-naive individuals aged ≥ 20 years at enrolment recruited during 2004-2021. NADC deaths were all deaths due to cancer, except those due to AIDS defining malignancies such as Kaposi sarcoma, certain types of non-Hodgkin lymphomas and cervical cancer. We estimated mortality rates and standardised mortality ratios (SMRs) using NADC mortality rates from the Spanish general population. We applied cause-specific Cox proportional hazard models, accounting for competing risk, with age as time-scale to identify prognostic factors for NADC mortality.

Results: Of the 17,978 study participants, 85% were men and median age was 35 years. NADC mortality rate was 1.58 (95% confidence interval: 1.36, 1.83) per 1,000 person-years (PY), 79% higher as that in the general population (SMR: 1.79, 95%CI 1.54, 2.07). The highest mortality rates were found for lung (0.57 per 1,000 PY; 95%CI 0.45, 0.73) and liver cancer (0.20 per 1,000 PY, 95%CI 0.13, 0.30). NADC mortality rates increased with age, while SMR decreased with age: NADC mortality in PLWH was three times higher than that of the general population in age groups under 50 years and gradually decreased to a similar rate than that of the general population in age groups over 50 years.
70 years (Figure). NADC mortality risk was higher in participants that acquired infection through heterosexual contact (Hazard Ratio: 1.50; 95%CI 1.08, 2.10) and injection drug use (HR: 1.89 (1.03, 3.47), compared to men having sex with other men. NADM mortality risk was associated with active smoking (HR: 2.23; 95%CI 1.05, 4.70), hepatitis C (HR: 1.59, 95%CI 0.98, 2.57) and hepatitis B virus (HR: 2.03, 95%CI 1.22, 3.38) and low CD4 count (HR: 9.76; 95%CI 5.35, 17.80 for CD4 < 200 cells/µL; HR: 4.17; 95%CI 2.31, 7.54 for CD4 200-349 cells/µL; HR: 2.61; 95%CI 1.62, 4.22 for CD4 350-499 cells/µL compared to CD4 ≥ 500 cells/µL).

Conclusions: Mortality due to NADC in PLWH was higher than in the general population, mainly at younger ages. It was associated mainly to immune suppression, smoking, and coinfection with hepatitis B and C, which are all preventable risk factors.

Funding: Gilead Scholarship Program for Biomedical Research (GLD19_00106), ISCIII- Miguel Servet CP19CIII - 00002 contract.

4. CHAMIGRENES ISOLATED FROM THE LAURENIA DENDROIDEA AGAINST NAEGLERIA FOWLERI

Javier Chao Pellicer1,2-3, Iñigo Arberas Jiménez1,2, Ines Sifaoui1,2, María Reyes Batlle1,2,3, Rubén Leocadio Rodríguez Expósito1,2, Patricia Pérez Pérez, Atteneri López Arencibia1,2,3, Javier Chao Pellicer, Desirée San Nicolás Hernández1,2, Ana Raquel Díaz Marrero4,5, José Javier Fernández Castro6,7, José Enrique Piñero Barroso1,2,3, Jacob Lorenzo Morales1,2,3

1Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, La Laguna, Spain. 2Departamento de Obstetricia y Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Universidad de La Laguna, La Laguna, Spain. 3Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERNED), Madrid, Spain. 4Instituto de Productos Naturales y Agrobiología, Consejo Superior de Investigaciones Científicas, La Laguna, Spain. 5Instituto Universitario de Bio-Órgánica Antonio González (IUBO AG), Universidad de La Laguna, La Laguna, Spain. 6Instituto Universitario de Bio-Órgánica Antonio González, La Laguna, Spain. 7Departamento de Química Orgánica, Universidad de La Laguna, La Laguna, Spain.

Introduction: Primary amoebic meningoencephalitis (PAM) is a central nervous system affecting disease caused by the opportunistic protozoa Naegleria fowleri. It is a fulminant disease with a rapid progression and affects mostly children and young adults who reported previous exposure to warm water bodies, such as lakes, hot springs or untreated swimming pools. The trophozoite stage of this amoeba penetrates the nasal cavity and migrates through the olfactory nerves to the brain causing infection and subsequent death a few weeks after the onset of the first symptoms. Although the disease has a case fatality rate of over 97%, currently available therapies are not at all effective and it is associated with a wide range of serious side effects. Therefore, the search for novel molecules with anti-Naegleria activity and low toxicity remains an urgent issue in the fight against the PAM. Some red algae of the Laurencia genus have shown great activity against diverse protozoa, including some parasites that belong to the free-living amoeba group.

Objectives: In the present study, the activity and cytotoxicity of different molecules obtained from the Laurencia dendroidea algae was evaluated. In addition, the presence of different metabolic events that are characteristic of the programmed cell death were evaluated in Naegleria fowleri trophozoites.

Methods: To evaluate the selectivity against Naegleria fowleri, activity assays were performed on two strains of the pathogen (ATCC® 30808™ and ATCC® 30215™) and, in turn, cytotoxicity assays against a murine macrophage cell line. Afterwards, those with a better selectivity index against Naegleria were used to study the induction of programmed cell death (PCD) process. These metabolic events studied were DNA condensation, plasma membrane damage, reduction of mitochondrial membrane potential and ATP levels or generation of ROS.

Results: As a result, the chamigrenes (+) - elatol, (+) - obtusol and (-) - elatol were the most active molecules against Naegleria fowleri trophozoites. Moreover, the type of cell death process that produces the (+)- elatol, the most active compound, was also determined, showing a programmed cell death induction in treated cells.

Conclusions: Hence, (+)- elatol could be considered as a good candidate for the development of new treatments against the primary amoebic meningoencephalitis.


10. SYNERGISTIC EFFECT BETWEEN ANTIBIOTICS AND TWO BACTERIOPHAGES CAPABLE OF INFECTING MULTIRESISTANT CLINICAL STRAINS OF KLEBSIELLA PNEUMONIAE

Abrar Senhaji, Jaime Esteban, Meritxell García Quintanilla

Fundación Jiménez Díaz, Madrid, Spain.

Introduction: Klebsiella pneumoniae is a gram-negative, facultative anaerobic bacteria belonging to the Enterobacteriaceae family. With a total of 8.56% of the isolates, it’s the fourth most frequent bacteria in Spain. The incidence of infections caused by carbapenemase-producing Enterobacteriaceae family is increasing every year.

Objectives: The objective is to study the combination effect of antibiotics in combination with two new bacteriophages against clinical MDR K. pneumoniae, evaluating the in vivo synergistic capacity of the bacteriophage and the study of combinations with antibiotics that can combat these infections.

Methods: Bacteriophages were isolated from sewage and hand-washing samples from the Hospital Universitario Fundación Jiménez Díaz (HUFJD). The synergistic antibacterial activity of the F4KP and F5KP bacteriophages was assigned by the modified broth microdilution method in multiwell 96 flat-bottom microplates (Thermo-Fischer) also known as Checkerboard. Experimental conditions were designed for the antibiotic-phage mixture and colistin, polymyxin B, fosfomycin, amikacin, doripenem and ciprofloxacin were tested along with the bacterial control at a final volume of 200 µl. Briefly, the culture was allowed to grow at an OD600 of 0.44 until 4 × 10^7 CFU was reached. Next, 50 µl of antibiotic at different concentrations was added to each well containing 50 µl of Mueller Hinton II 90922 broth (Millipore, Sigma Aldrich, Merck) supplemented with 10 mM CaCl2

Summary of synergistic effect between F4KP, F5KP and antibiotics against KPS K. pneumoniae strain
and 10 mM MgSO4. In addition, 50 µl of each phage dilution (109 to 105 PFU) was added to the suspension and 100 µl of bacterial suspension was added to the mixing wells. Plates were incubated at 37 °C overnight and FIC (fractional inhibitory concentration) was calculated according to bacterial growth measured at OD595. This experiment was performed in duplicate.

**Results:** Bacteriophage F4KP was found to have a synergistic effect in combination with polymyxin B (FIC = 0.162) and additive effect with colistin and doripenem (0.501 and 0.510, respectively). F5KP showed additive effect in combination with polymyxin B, colistin and doripenem obtaining an FIC of 0.5001, 0.600 and 0.501 respectively. The checkerboards performed proved that F4KP and F5KP showed no effect in combination with fosfomycin, ciprofloxacin and amikacin.

**Conclusions:** The F4KP and F5KP bacteriophages have shown synergistic and additive effects in combination with certain antibiotics and to combat infections caused by clinical strains of multiresistant K. pneumoniae. We tested which phage-antibiotic combinations could have a clinical use and which antibiotics don't produce any effect in combination with these bacteriophages. It could be a promising alternative for infections caused by MDR bacteria that cannot be treated by conventional antibiotics alone.

Funding: CIBER-Enfermedades Infecciosas.

13. ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND MEROPENEM, ALONE AND IN COMBINATION, AGAINST KLEBSIELLA PNEUMONIAE HIGH-RISK CLONES PRODUCING NOVEL KPC VARIANTS WITH COLLATERAL SENSITIVITY TO CARBAPENEMS

Marta Hernández García, Marta Nieto-Torres, Marina Domínguez, Patricia Ruiz-Garbajosa, Rafael Cantón

**Hospital Universitario Ramón y Cajal, Madrid, Spain.**

**Introduction:** Ceftazidime-avibactam (CAZ-AVI) has been introduced in clinical practice to combat difficult-to-treat infections caused by carbapenem-resistant Enterobacteriales, including KPC-producing Klebsiella pneumoniae (KPC-Kp). Nevertheless, emergence of CAZ-AVI resistance due to novel KPC enzymes in Kp high-risk clones, such as ST307-Kp, is increasing. Additionally, clinical isolates expressing mutated KPC enzymes frequently exhibit a restored susceptibility to carbapenems, phenomenon known as “collateral sensitivity” (CS).

**Objectives:** To explore two potential strategies to treat CAZ-AVI resistant KPC-ST307-Kp infections based on the CS effect of CAZ-AVI: combined therapy of ceftazidime-avibactam and carbapenems (CAZ-AVI+CBs) and to recuperate the monotherapy use of carbapenems.

**Methods:** Between 2018-2023, we detected in our hospital a total of 7 mutated KPC variants (KPC-31, KPC-46, KPC-61, KPC-62, KPC-66, KPC-92 and KPC-150) in clinical ST307-Kp isolates. MICs were determined using standard broth microdilution (EUCAST-2023 breakpoints). Synergy assessments were performed by crossing the gradient strips at a 90° angle at the respective MICs of each antibiotic (Etest synergy test). Results were expressed using the fractional inhibitory concentration index [FICI = (MIC-A in combination/MIC-A alone)+(MIC-B in combination/MIC-B alone)]. FICI ≤ 0.5 was considered as synergistic, 0.5 < FICI ≤ 4 as indifferent and FICI > 4 as antagonistic. The in vitro effect of CAZ-AVI, meropenem (MER) and CAZ-AVI+MER combination was evaluated performing killing kinetics (KC) studies in a selection of KPC-ST307-Kp mutants (KPC-31-Kp, KPC-62-Kp, KPC-66-Kp and KPC-150-Kp) and in a KPC-3-ST307-Kp strain. Tested antibiotic concentrations were: (-2)xMIC, 1xMIC, 2xMIC and 4xMIC; and activity was assessed at 0h, 1h, 3h, 5h, 7h and 24h. Synergy was defined as ≥ 2log10 CFU/ml decrease.

**Results:** All KPC-ST307-Kp mutants showed resistance to CAZ-AVI (MIC range: 32-128 mg/L) and CS to meropenem (MIC range: ≥ 0.06-8 mg/L) (Table). The Etest synergy test revealed that the CAZ-AVI+MER combination was synergistic in all clinical KPC-ST307-Kp mutants (FICI < 0.5) (Table). The KC study demonstrated a synergistic effect of the CAZ-AVI+MER combination in all concentrations even below the MIC of both antibiotics. Moreover, meropenem was also active at the MIC concentration in the KPC-62-ST307-Kp and at higher concentrations (≥ 2xMIC) in KPC-31-ST307-Kp, KPC-66-ST307-Kp and KPC-150-Kp mutants (Figure).

**Conclusions:** Our study demonstrated that the combination of CAZ-AVI and meropenem is synergistic and that meropenem is active against KPC-Kp mutants. Therapies based on combination or collateral sensitivity could be a potential therapeutic option to treat infections caused by Kp-KPC mutants and could help prevent the evolution of CAZ-AVI resistance.

Funding: FIBio-Intramural-research grant (2021/0442), ISCIII-research grant (PI22/01283), and CIBER de Enfermedades Infecciosas (CIBERINFEC) (CB21/13/0084).

17. TELOMERE LENGTH IN AVIREMIC PWH: HOW DIFFERENT IS IT FROM PERSONS WITHOUT HIV?

Introduction: Blood telomere length (BTL) attrition is a surrogate biomarker of immunosenescence and aging associated with HIV infection. BTL recovers in long-term virologically suppressed PWH, but it is unknown if recovery is complete compared with persons without HIV.

Objectives: In a prospective cohort of aviremic HIV infected adults to evaluate after six years of follow-up: 1. Sequential changes in BTL. 2. Differences in BTL versus HIV negative persons matched by age and sex, and versus adults aged 60-80 years matched by sex.

Methods: Prospective 6-year observational study assessing the evolution of BTL in virologically suppressed PWH and a cross-sectional analysis comparing BTL with age and sex-matched blood donors, and sex matched persons older than 60 from a general population cohort. Relative BTL was determined by monochromatic quantitative multiplex PCR assay and expressed as the ratio of telomere to single-copy gene (T/S).

Results: We included 128 PWH, 128 blood donors, and 128 persons over 60. Median age at 6 years of follow-up was 55 (IQR: 51.0-58.3), 55.2 (IQR: 67.5-73) and 55.2 (IQR: 51.3-59) years, respectively. 27.3% had ever been injected drugs users, 92.2% were Caucasian, 34.4% resolved hepatitis C virus infection, 90.6% positive CMV IgG and 41.5% with ≥ 1 comorbidity. At 6 years of follow-up, the median time with known HIV-1 infection and virological suppression were 23.6 (IQR: 18.5-27.9) and 13.2 (IQR: 12.1-13.7) years, respectively. Nadir/current median CD4 count were 181.5 (IQR: 80.5-255) and 773.5 (IQR: 540-1,020) cells/μL, and the median CD4/CD8 ratio was 1.11 (IQR: 0.80-1.44). In the elderly population 9.6%, 45.2% and 45.2% were active/former smokers, respectively. BTL of PWH increased after 6 years of virological suppression (median BTL at baseline 1.04 (IQR: 0.93-1.16) vs. 1.07 (IQR:0.95-1.17) after 6 years [p < 0.001]), without reaching the median BTL of blood donors of the same age and sex (1.28 [IQR: 1.11-1.45]; p < 0.001), but significantly above the median BTL of the older than 60 general population group (0.89 [IQR: 0.77-0.97]; p < 0.001) (Figure).

Conclusions: During the 6 years of follow-up the median BTL of aviremic PWH increased but still was shorter than the BTL of age/sex matched blood donors. However, compared to the elderly population our data do not support that aviremic PWH have a very pronounced BTL shortening.

18. DETECTION/IDENTIFICATION OF THE MPXV VIRUS AND/OR OTHER ORTHOPOXVIRUSES BY MOLECULAR METHODS: CIBERINFEC QUALITY CONTROL

Ruben Cebrián1,2,3, Miguel J. Martínez4,5, Jessica Navero-Castillejos4, Anabel Negredo4,6, Adolfo de Salazar4,8, Juan Carlos Galán6, Estrella Rojo Molinero6,9, Eduardo Lagarejos9, Carmen Muñoz-Almagro3,10, Águeda Hernández Rodríguez3, José Antonio Lepe14,15, Andrés Antón Pagarakas16, Sonia Pérez Castro17,18, María Isabel Zamora Cintas19, Marta Domínguez-Gil González20, Jordi Niubo Bosch21,22, Almudena Gutiérrez Arroyo23, Ana Vázquez24, Federico García1,2,3, María Paz Sánchez-Seco Fariñas1,5, Adolfo de Salazar1,2,3, Juan Carlos Galán7,8,

1Hospital Universitario Clinico San Cecilio, Granada, Spain. 2Instituto de Investigación Biosanitaria Ibs Granada, Granada, Spain. 3Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 4Hospital Clinico de Barcelona, Barcelona, Spain. 5ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clinic, Barcelona, Spain. 6Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain. 7Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCS), Madrid, Spain. 8Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 9Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain. 10Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain. 11Hospital Sant Joan de Deu, Barcelona, Spain. 12Departamento de Medicina, School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain. 13Servei de Microbiologia, Laboratori Clinic de la Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. 14Hospital Universitario Virgen del Rocío, Sevilla, Spain. 15Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain. 16Hospital Universitario Vall d’Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain. 17Complejo Hospitalario Universitario de Vigo, Vigo, Spain. 18Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain. 19Hospital Central de la Defensa, Madrid, Spain. 20Hospital Universitario Río Hortega, Valladolid, Spain. 21Laboratori Clinic Territorial Metropolitana Sud, Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS), Hospital de llobregat, Spain. 22Bellvitge Biomedical Research Institute (IDIBELL), Hospital de llobregat, Spain. 23Hospital Universitario La Paz, Madrid, Spain.
**Results:** Of the 14 participating centers, 2 performed determinations only for OPXV and 4 only for MPXV, while the rest of the centers performed determinations for both viruses. Among the 14 centers, 7 different commercial assays were used, with the most commonly used kit being LightMix Modular Orthopox/Monkeypox Virus (Roche®). Of the 12 centers that performed determinations for MPXV, a concordance of between 62.5% (1 center) and 100% (11 centers) was observed for eluate samples and between 75.0% (1 center) and 100% (10 centers) for serum samples. Of the 10 centers performing determinations for OPX, a concordance of 100% was observed for eluate samples and between 87.5% (6 centers) and 100% (4 centers) for serum samples in the diagnosis of OPXV. A false negative was repeatedly observed in 6 different centers in a serum sample for the diagnosis of OPXV, in a sample with Ct values at the limit (39). On the other hand, one center reported false positives in the diagnosis of MPXV in samples positive for OPXV due to cross-reactivity with the TaqMan™ Monkeypox Virus Microbe Detection Assay (Thermo Fisher) technique.

**Conclusions:** The quality control results show a high correlation with those of the reference center. Specific cases of false positives/negatives were resolved thanks to this quality control. This study highlights the need for external quality controls when implementing new determinations in the microbiological diagnosis of infectious diseases.

Funding: This study was funded by the AES of CIBERINFEC MONK-POX-ESP22 World Package 5 (INFEC22PI01WPS).

---

### 26. EUCAST-OBTAINED OOLOROFIM MICS AGAINST NON-FUMIGATUS ASPERGILLUS CLINICAL ISOLATES: HIGH AGREEMENTS BETWEEN VISUAL INSPECTIONS AND SPECTROPHOTOMETRIC READINGS

**Julia Serrano Lobo**, Ana Gómez, Elena Reigadas, Patricia Muñoz, Pilar Escribano, Jesús Guinea

**Hospital General Universitario Gregorio Marañón, Madrid, Spain.**

**Introduction:** We previously showed a high agreement between olorofim MIC values obtained by visual inspection and spectrophotometric readings against *Aspergillus fumigatus* sensu lato following EUCAST methodology (DOI: 10.1128/aac.00849-22).

**Objectives:** The objective of this work is to expand those comparisons against non-fumigatus *Aspergillus* spp. clinical isolates.

**Methods:** A total of 87 participating hospitals, covering all Spanish regions, stored, and identified *Aspergillus* spp clinical isolates – regardless their clinical significance – collected from the 1st of February to the 31st of March 2022. We here report a preliminary analysis of isolates (n = 439) collected at 55 hospitals and belonging to sections *Flavi* (n = 89), *Nidulantes* (n = 55), *Nigri* (n = 192), and *Terrei* (n = 103).

Antifungal susceptibility to olorofim was performed according to EUCAST 9.4 methodology. Visually-set MICs were compared with spectrophotometrically-obtained MICs (combinations of either ≥ 95% or ≥ 90% fungal growth inhibition endpoints compared to drug-free control endpoints and read at 540 nm). Essential (≥ 1 twofold dilution) agreement values were calculated and wild-type upper limits (wt-ULs) were set according to the eye-ball method (calculated as two-fold dilutions higher than modal MIC).

**Results:** MIC distributions are shown in the Table. With only a few exceptions, olorofim MIC values were up to 0.03 mg/L against *Flavi* and *Terrei*, 0.06 mg/L against *Nidulantes*, and 0.125 mg/L against *Nigri*. Essential agreement between visually-obtained MIC values and spectrophotometric-obtained MIC values were higher when the ≥ 95% fungal growth inhibition endpoint was used (Flavi and *Terrei* [98.1%]; *Nidulantes* [96.4%]), except for section *Nigri* (Table). The fungal growth inhibition endpoints that led to modal MIC and wt-UL values identical to the ones obtained by visual inspections were: *Flavi* section (≥ 95%), *Nidulantes* section (≥ 95% or ≥ 90%), *Nigri* section (≥ 90%). In section *Terrei*, both endpoints led to lower modal MICs and wt-UL values (Table).

**Conclusions:** MICs of olorofim against non-fumigatus *Aspergillus* were low, showing the activity of the drug against the isolates tested. MIC values obtained by spectrophotometer and by visually inspection showed high agreement values, specially using the 95% fungal growth inhibition endpoint, against all section except *Nigri*.

Funding: This work was supported by grants PI21/00450 from Fondo de Investigación Sanitaria (FIS. Instituto de Salud Carlos III. Plan Estatal de Investigación Científica, Técnica y de Innovación 2021 – 2023 (PEICITI)). The study was co-funded by the European Regional Development Fund (FEDER) ‘A way of making Europe’. This study was partially funded by F2G.

---

### 27. EUCAST-OBTAINED MIC OF AZOLES AND AMPHOTERICIN B AGAINST ASPERGILLUS FUMIGATUS SENSUS STRICTO: SPECTROPHOTOMETRIC READINGS VISUAL INSPECTIONS SHOWED HIGH AGREEMENT

**Julia Serrano Lobo**, Ana Gómez, Elena Reigadas, Patricia Muñoz, Pilar Escribano, Jesús Guinea

**Hospital General Universitario Gregorio Marañón, Madrid, Spain.**

**Introduction:** Previous studies show high essential and categorical agreements between MICs of azoles and amphotericin B obtained by spectrophotometric readings and visual inspection against *Aspergillus fumigatus*, according to EUCAST methodology. Visual MIC readings

<table>
<thead>
<tr>
<th>Sections</th>
<th>Endpoints used to obtain the MIC</th>
<th>MIC distributions (no. of isolates at each MIC, mg/L)</th>
<th>EA (%)</th>
<th>wt-UL</th>
<th>% non-wild isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.001 0.002 0.004 0.008 0.016 0.03 0.06 0.125 0.25 ≥ 0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Flavi (n = 89)**: Visual 0 0 0 10 64 14 0 0 0 1 98.9 0.06 1.1

**Nidulantes (n = 55)**: Visual 0 0 0 3 21 34 10 0 1 0 99.6 0.06 3.6

**Nigri (n = 192)**: Visual 0 0 0 3 9 19 0 0 0 1 98.4 0.06 0.5

**Terrei (n = 103)**: Visual 0 0 0 1 9 119 0 0 0 0 98.4 0.06 1.0
required experiences and may lead to some degree of subjectivity. In contrast, spectrophotometric reading is more objective and automated and thus requires less skilled readers.

**Objectives:** The objective of this work is to assess such comparisons, paying special attention to the MIC distributions (modal MIC and wild type upper limits [wt-UL]) obtained by using each endpoint.

**Methods:** A total of 87 participating hospitals, covering all Spanish regions, stored, and identified *Aspergillus* spp clinical isolates – regardless their clinical significance – collected from the 1st of February to the 31st of March 2022. We here report a preliminary analysis of *A. fumigatus* sensu stricto isolates (n = 624) collected at 55 hospitals, including 15 azole-resistant isolates with the following cyp51A gene mutations: TR34-L98H (n = 12), and other substitutions (n = 3).

Antifungal susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole, and isavuconazole was performed according to EUCAST 9.4 methodology. Visually-set MICs were compared with spectrophotometrically-obtained MICs (fungal growth reduction ≥ 95% and ≥ 90% compared to control and read at 540 nm); essential and categorical agreement values were 98.8% and 99.4% (≥ 95% fungal inhibition endpoint), and 96.5% and 99.6% (≥ 90% fungal inhibition endpoint), respectively. No major visual errors were found with amphotericin B or voriconazole. Very few very major errors were detected in itraconazole (n = 2), isavuconazole (n = 1), or posaconazole (n = 2), one involving an isolate harbouring the TR34-L98H substitutions. Values of wt-UL were not affected by the fungal inhibition endpoints studied; however the modal MIC in the distributions may be one two-fold dilution lower when the ≥ 90% fungal inhibition endpoint was used.

**Results:** Essential and categorical agreement values were 98.8% and 99.4% (≥ 95% fungal inhibition endpoint), and 96.5% and 99.6% (≥ 90% fungal inhibition endpoint), respectively. No major visual errors were found with amphotericin B or voriconazole. Very few very major errors were detected in itraconazole (n = 2), isavuconazole (n = 1), or posaconazole (n = 2), one involving an isolate harbouring the TR34-L98H substitutions. Values of wt-UL were not affected by the fungal inhibition endpoints studied; however the modal MIC in the distributions may be one two-fold dilution lower when the ≥ 90% fungal inhibition endpoint was used.

**Conclusions:** MICs of azoles and amphotericin B against *A. fumigatus* sensu stricto obtained either by spectrophotometer or visually showed very high agreement. Essential agreement was slightly higher when spectrophotometric endpoint was ≥ 95%. Categorical agreement was almost identical.

**Funding:** This work was supported by grants PI21/00450 from Fondo de Investigación Sanitaria (FIS. Instituto de Salud Carlos III. Plan Estatal de Investigación Científica, Técnica y de Innovación 2021 – 2023 (PEICTI)). The study was co-funded by an investigational grant by Gilead Ltd.

### 31. INFLUENCE OF THE GEOGRAPHICAL ORIGIN OF THE PARASITE ON THE SIZE OF *S. HAEMATOBION SUB-SAHARIAN EGGS*

**Maria Cecilia Fantozzi**, 2 Marta Reguera-Gómez, 1 Maria Adela Valero, 1 Patricio Artigas, 1,2 Alejandra de Elías-Escribano, 2 María Pilar Luzón-García, 1 Joaquín Salas-Coronas, 4 Jerôme Boissier, 4 Santiago Mas-Coma, 1,2 María Dolores Bargues 1,2

1 Departamento de Parasitología, Facultad de Farmacia, Universidad de Valencia, Valencia, Spain. 2 Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFE). Instituto de Salud Carlos III, Madrid, Spain. 3 Unidad de Medicina Tropical, Hospital Universitario Pontevedra, A Coruña, Spain. 4 Host Pathogen Environments Interactions (IHPE) Laboratory, University of Montpellier, CNRS, IFREMER, University of Perpignan, Perpignan, France.

**Introduction:** Schistosomiasis is a Neglected Tropical Disease caused by trematode species of the genus Schistosoma. Both, autochthonous and imported cases of urogenital schistosomiasis have been described in Europe. Schistosome eggs play an important role in schistosomiasis diagnosis. Previous studies characterizing *S. haematobium* eggs showed great variability in their phenotype measurements, demonstrating the necessity of new studies focused on the influence of distinct factors that may potentially be involved, such as the geographical origin of the parasites.

**Objectives:** In the present work, the intraspecific variability of *Schistosoma haematobium* eggs, found in sub-Saharan migrants present in Spain, associated with the country of origin of the parasite, is characterized, as well as, the phenotypes present in each country, using the previously proposed methodology.

**Methods:** Only eggs considered “pure” *S. haematobium* by genetic characterization (rDNA ITS-2 and mtDNA cox1) have been used. A total of 162 eggs obtained from 20 migrants from Mali (n = 11), Mauritania (n = 4) and Senegal (n = 5) living in Spain and diagnosed with urogenital schistosomiasis, were included in the study. For the morphometric phenotyping seventeen standardised measurements were applied to each individualized egg. Image Pro Plus software was used. CVA and Mahalanobis distances were performed using the CLIC package and the available online XYOM software.

**Results:** Three morphotype classes were described based on the results of the Egg Shape Ratio (ESR) (Figure): (a) morphotype round (ESR < 2.00) (N = 55, 34.0%); (b) morphotype elongated (2.01 < ESR < 2.29) (N = 62, 38.3%); and (c) morphotype spindle (ESR > 2.30) (N = 45, 27.7%). Overall, *S. haematobium* eggs from Senegal showed the
greatest length, area, perimeter and radius. Eggs from Mali have greater roundness and spine medium width (SMW), while Mauritania eggs are characterized by the smallest radius and width. Mahalanobis distances, when all egg measurements were analyzed, showed differences between: (i) Mali-Mauritania, Mali-Senegal and Mauritania-Senegal in the round morphotype; (ii) Mali-Mauritania and Mauritania-Senegal in the elongated morphotype; and (iii) Mauritania-Senegal in the spindle morphotype. Mahalanobis distances, when spine variables were analyzed, showed differences between Mali-Senegal in the round morphotype (Table).

Conclusions: This is the first phenotypic study performed on individually genotyped “pure” S. haematobium eggs, allowing the assessment of the intraspecific morphological variations associated with the geographical origin of the schistosome eggs. The results suggest that S. haematobium eggs show great shape variability within the three populations, and, unexpectedly, round or elongated shapes are not always the most common phenotypes of genetically “pure” S. haematobium eggs, as previously believed.

Funding: Red de Investigación de Centros de Enfermedades Tropicales—RICET (RD16/0027/0013 and RD16/0027/0023), ISCIII-Subdirección General de Redes y Centros de Investigación Cooperativa RETICS, Ministry of Health and Consumption and European FEDER funds, Madrid; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC) (CB21/13/00056 and IM22/INF/6), ISCIII, Ministry of Science and Innovation and European Union—NextGenerationEU; PROMETEO Program, Programa de Ayudas para Grupos de Investigación de Excelencia (2021/004), Generalitat Valenciana, Valencia. M.C.F. is currently a recipient of a fellowship (CIAPOS/2021/166).

32. ZOONOTIC ROCAHEPEVIRUS RATTI IN RODENTS IN SPAIN

Javier Caballero Gómez1,2,3, Tomás Fajardo Alonso1,2,3, Ignacio García Bocanegra1,2, Adrián Beato Benítez1, Rosario Panadero1, Remigio Martínez2,3, Moisés González1,2, Rafael Guerra1, Débora Jiménez Martín1, Eva Martínez Nevado1, David Cano Terriza1, Pilar Soriano1, Miguel Angel Quevedo1, Andrea González1, Santiago Borragán1, Raúl Cuadrado Matías1, Dietmar Crailsheim1, Andrea Carretero Alonso1, Antonio Rivero1,2, Antonio Rivero Juárez2,3

1Departamento de Sanidad Animal, Grupo de Investigación GISAZ, UIC Zoonosis y Enfermedades Emergentes ENZODEM, Universidad de Córdoba, Córdoba, Spain. 2Grupo de Virología Clínica y Zoonosis, Unidad de Enfermedades Infecciosas, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain. 3Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 4Investigación en Sanidad Animal: Galicia (Grupo INVESAGA), Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain. 5Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad de Extremadura, Cáceres, Spain. 6Departamento de Sanidad Animal, Facultad de Veterinaria, Campus de Excelencia Internacional Regional “Campus Mare Nostrum”, Murcia, Spain. 7Centro de Conservación Zoo Córdoba, Córdoba, Spain. 8Zoo Aquarium of Madrid, Madrid, Spain. 9Río Safari Elche, Alicante, Spain. 10Zoo Botánico Jerez, Jerez de la Frontera, Spain. 11Fundación Zoo Santillana, Santillana Del Mar, Spain. 12Parque de la Naturaleza de Cabárceno, Obregón, Spain. 13Grupo Sanidad y Biotecnología (SaBio), Instituto de Investigación en Recursos Cinegéticos, Ciudad Real, Spain. 14Centro de Recuperación de Primates Fundación Mona, Girona, Spain. 15Centro de Rescate de Primates Fundación Rainfer, Madrid, Spain.

Introduction: An increasing number of cases of acute and chronic hepatitis associated with the recently considered zoonotic Rocahepevirus ratti (RHEV) has been reported during the last few years in Hong Kong, Canada, China, and more recently in Spain. Although rodents are the main reservoirs of this emerging virus, large-scale studies to assess the circulation of this pathogen in these species have not been conducted to date in Spain.

Objectives: The main aims of this study were to determine the prevalence of RHEV infection in urban and periurban rodents from Spain and to assess the risk of transmission from these to other sympatic species, including humans.

Methods: During the period 2020-2022, liver samples from 342 rodents, including 212 Norway rats (Rattus norvegicus), 60 water voles (Arvicola scherman), 51 mouse (Mus musculus), 14 European moles (Talpa europaea) and 5 black rats (Rattus rattus), were collected throughout Spain. The presence of active RHEV infection was assessed by two real time RT-PCRs assays and phylogenetic analyses were carried out using two nested RT-PCRs.

Results: A total of 73 (21.3%; 95%CI: 17.1-25.8) of the 342 analyzed rodents were positive to RHEV RNA. By species, the prevalence of infection was 29.7% in Norway rats, 19.6% in mouse and 0% in water voles, European mole and black rats. Infected rodents were detected in seven (58.3%) of the 12 provinces sampled, with frequency of positivity ranging from 6.3% to 70.5%. Phylogenetic analyses showed a nucleotide identity of 89.0-99.5% with other RHEV previously detected in rodents and humans from different European countries, including Spain.

Conclusions: The prevalence of RHEV detected in Norway rats and mouse populations of this country is of public health concern. The high homology with other hepevirus sequences obtained in these species and in humans point the risk of zoonotic transmission of RHEV from urban and periurban rodents.

Funding: This work was supported by the Ministerio de Sanidad (RD12/0017/0012) integrated in the Plan Nacional de I+D+i and cofinanced by the ISCIII-Subdirección General de Evaluación and the Fon-
Introduction: Host-encoded microRNA (miRNA) response to SARS-CoV-2 infection has been reported to be altered mostly in relation to severe COVID-19 cases. However, there is scarce information in relation to host miRNAs profiles in asymptomatic or mild symptomatic COVID-19 cases, that might also provide important insights into both viral pathogenesis and patient management.

Objectives: The aim of the present study was to determine a potential miRNAs profile to be altered in asymptomatic/mild COVID-19 cases in different biological samples such as serum or oropharyngeal/saliva samples.

Methods: Circulating miRNAs from serum and oropharyngeal/saliva belonging to eight asymptomatic or mild symptomatic COVID-19 patients and eight age and gender matched healthy controls were determined by NGS. RNA was isolated and converted into miRNA samples.

Results: We observed 18 miRNAs significantly dysregulated in serum from asymptomatic/mild symptomatic COVID-19 patients and eight age and gender matched healthy controls were determined by NGS. RNA was isolated and converted into miRNA NGS libraries to subsequent sequence on a NextSeq (Illumina Inc.) instrument. In silico analysis were performed for target prediction.

Limit of Detection for the Dual-LAMP-Pspp assay was 1.22 parasites/µl and 5.82 parasites/µl when column or saline DNA extraction methods were used, respectively, without differences in results. No cross-reactivity with any of the samples tested was found with Dual-LAMP-Pspp assay.

Results: Limit of Detection for the Dual-LAMP-Pspp assay was 1.22 parasites/µl and 5.82 parasites/µl when column or saline DNA extraction methods were used, respectively, without differences in results. No cross-reactivity with any of the samples tested was found with Dual-LAMP-Pspp assay.

35. ALTERED MICRORNA EXPRESSION IN SERUM AND SALIVA SAMPLES FROM ASYMPTOMATIC AND MILD COVID-19 CASES

Angélica Domínguez de Barros1, Malena Gajate Arenas1, Omar García Pérez2, Candela Sirvent Blanco1, Javier Chao Pellicer1,2, Roberto Dorta Guerra1,3, José E Piñero1,2,4, Jacob Lorenzo Morales1,2,4, Elizabeth Córdoba Lanús1,2

1Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna, La Laguna, Santa Cruz de Tenerife, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), Madrid, Spain. 3Departamento de Matemáticas, Estadística e Investigación Operativa, Facultad de Ciencias, Universidad de La Laguna, La Laguna, Santa Cruz de Tenerife, Spain. 4Departamento de Obstetricia y Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxcológia, Medicina Legal y Forense y Parasitología, La Laguna, Santa Cruz de Tenerife, Spain.

Introduction: Host-encoded microRNA (miRNA) response to SARS-CoV-2 infection has been reported to be altered mostly in relation to severe COVID-19 cases. However, there is scarce information in relation to host miRNAs profiles in asymptomatic or mild symptomatic COVID-19 cases, that might also provide important insights into both viral pathogenesis and patient management.

Objectives: The aim of the present study was to determine a potential miRNAs profile to be altered in asymptomatic/mild COVID-19 cases in different biological samples such as serum or oropharyngeal/saliva samples.

Methods: Circulating miRNAs from serum and oropharyngeal/saliva belonging to eight asymptomatic or mild symptomatic COVID-19 patients and eight age and gender matched healthy controls were determined by NGS. RNA was isolated and converted into miRNA NGS libraries to subsequent sequence on a NextSeq (Illumina Inc.) instrument. In silico analysis were performed for target prediction.

Results: We observed 18 miRNAs significantly dysregulated in serum from asymptomatic/mild symptomatic COVID-19 cases when compared to healthy controls, being miR-485-3p and miR-143 the most up-regulated (Log2FC = 5.24, FDR = 0.00027). The principal component analysis (PCA) revealed that the miRNA profile based on 500 dysregulated miRNAs could independently classified serum from nasopharyngeal samples of COVID-19 cases.

Conclusions: This study demonstrates that SARS-CoV-2 infection induces a robust host miRNA response also in asymptomatic or mild COVID-19 cases. miR-485-3p is a promising useful inflammatory biomarker while miR-143-5p may efficiently combat SARS-CoV-2 by reducing host cell apoptosis via mTOR. Validation of the present findings in a large patient cohort are warranted.

Funding: CB21/13/00100 (CIBERINFECC), Instituto de Salud Carlos III, Spain.

36. MALARIA DIAGNOSIS USING A COMBINED SYSTEM OF A SIMPLE AND FAST EXTRACTION METHOD WITH A LYOPHILISED DUAL-LAMP ASSAY IN A NON-ENDEMIC SETTING

Alexandra Martín Ramírez1,2, Lourdes Barón Argós3, Marta Lanza Suárez3, Ana Pérez-Ayala3, José M. Rubio Muñoz2

1Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), Instituto de Salud Carlos III, Madrid, Spain. 2Laboratorio de Malaria y Parásitos Emergentes, Instituto de Salud Carlos III, Madrid, Spain. 3Laboratorio de Malaria y Parásitos Emergentes, Instituto de Salud Carlos III, Madrid, Spain. 4Servicio de Microbiología, Hospital Universitario Doce de Octubre, Madrid, Spain. 5Laboratorio de Malaria y Parásitos Emergentes, Instituto de Salud Carlos III, Madrid, Spain.

Introduction: Malaria is the most important parasitic disease in humans, with 247 million malaria cases in 2021 worldwide. Malaria LAMP methods are more sensitive and specific than conventional methods, however they have some limitations.

Objectives: This study aims to solve some limitations of LAMP assays with the optimization and validation of a Dual-LAMP assay using a simple purification method, two ways of result readings, the incorporation of a reaction control and lyophilisation of reagents.

Methods: A total number of 523 samples were used in this study. Six Dual-LAMP assays (Dual-LAMP-Plasmodium spp., Dual-LAMP-P. falciparum, Dual-LAMP-P. vivax, Dual-LAMP-P. ovale, Dual-LAMP-P. malariae and Dual-LAMP-P. knowlesi), were validated retrospectively with column purification method; meanwhile 95 samples were used prospectively with Dual-LAMP-Pspp and Dual-LAMP-Reaction Control assays, using a new saline extraction and the column purification methods. Result readings were based on colorimetry and fluorescence (Figure). Nested Multiplex-PCR was the reference method. Dual-LAMP-RC and Dual–LAMP-Pspp assays were lyophilised in set of three tubes and assessed with 64 samples extracted by both purification methods.

Results: Limit of Detection for the Dual-LAMP-Pspp assay was 1.22 parasites/µl and 5.82 parasites/µl when column or saline DNA extraction methods were used, respectively, without differences in results. No cross-reactivity with any of the samples tested was found with Dual-LAMP-Pspp assay. Quantitative result obtained with the fluorescence reading showed a linear relationship with parasite concentration (R2 = 0.618 with saline and R2 = 0.779 with column extracted samples). Retrospective assessment of the six Dual-LAMP assays provided 100% sensitivity for the Dual-LAMP-Pf and Dual-LAMP-Pv assays and 100% specificity for Dual-LAMP-Pf, Dual-LAMP-Pm, Dual-LAMP-Po and Dual-LAMP-Pk assays (Table). Agreement between the Dual-LAMP-Pspp assay with column and saline purified samples was 88.04% for colorimetric and 90.22% for fluorescence reading. Dual-LAMP-RC assay showed color change and fluorescence amplification with both purification methods in Plasmodium spp. positive and negative samples, meanwhile no-DNA controls were negative. Lyophilised sets of three tubes yield 100% agreement between Dual-LAMP-Pspp assay and NM-PCR with both extraction and result readings methods.

Figure 1. Each gene’s fold change (FC) is plotted against its mean expression among all serum samples. All significantly differentially expressed genes are marked in red. Significant changes are defined as p-value<0.001, FDR<0.01, and Log2FC>2.
Introduction: Epigenetic age is an accurate predictor of biological age based on changes in DNA methylation. Accelerated epigenetic ageing can occur in untreated HIV infection and is partially reversible with effective antiretroviral therapy (ART).

Objectives: To assess a long-term comparison of epigenetic aging dynamics in people with HIV during untreated HIV infection and during suppressive ART.

Methods: In this longitudinal study conducted over 17 years, we applied 5 established epigenetic age estimators (Horvath’s clock, Hannum’s clock, SkinBlood clock, PhenoAge and GrimAge) in peripheral blood mononuclear cells in Swiss HIV Cohort Study participants before or during suppressive ART. All participants had a longitudinal set of samples available at four timepoints. We assessed epigenetic age acceleration (EAA) and a novel rate of epigenetic aging.

Results: We analysed 80 people with HIV from the Swiss HIV Cohort Study. 52 (65%) of patients were men, 76 (95%) were white, and the median patient age was 43 years (IQR 37.5–47) years. Per year of untreated HIV infection (median observation 8.08 years, IQR 4.83–11.09), mean EAA showed little change in the mean EAA during untreated HIV infection; and 0.65 years for Horvath, 0.61 years for Hannum, 0.74 years for SkinBlood-EAA, and -0.49 years (-0.64 to -0.35) for PhenoAge-EAA. These findings indicate that people with HIV epigenetically aged by 1.47 years for Horvath, 1.43 years for Hannum, 1.36 years for SkinBlood, and 1.69 years for PhenoAge, per year of untreated HIV infection; and 0.65 years for Horvath, 0.61 years for Hannum, 0.74 years for SkinBlood, and 0.51 years for PhenoAge, per year of suppressive ART. GrimAge showed little change in the mean EAA during untreated HIV infection (0.1 years, 0.02 to 0.19) and suppressive ART (-0.05 years, -0.12 to 0.02). We obtained very similar results using the rate of epigenetic aging. Contribution of multiple HIV-related, antiretroviral, and immunological variables to epigenetic aging was not significant.

Conclusions: In a longitudinal study over 17 years, epigenetic age acceleration during untreated HIV infection and deceleration during suppressive ART, highlighting the importance of limiting the duration of untreated HIV infection including early ART start. Funding: Swiss HIV Cohort Study, Swiss National Science Foundation, Gilead Sciences.

37. EPGENETIC AGE ACCELERATES BEFORE ANTIRETROVIRAL THERAPY AND DECELERATES AFTER VIRAL SUPPRESSION IN PEOPLE WITH HIV IN SWITZERLAND: A LONGITUDINAL STUDY OVER 17 YEARS

Isabella Schoepf1, André Esteban-Cantos2, Christian W. Thorball1, Berta Rodés3, Peter Reiss4, Javier Rodriguez-Centeno4, Carlotta Riebensahm5, Dominique L Braun5, Catia Marzolini6, Marco Seneghini7, Enos Bernasconi8, Matthias Cavassini9, Isabella Schoepf1, Patricia Echevarría2, Diana Hernández2, Marco A. Fernández3, Julíà Blanco1, Eugenia Negredo1, Marta Massanella1

1IrsiCaixa-AIDS Research Institute and Germans Trias i Pujol Health Research Institute, Badalona, Spain. 2Fundación Lluita contra les Infeccions, Germans Trias Pujol Health Research Institute, Badalona, Spain. 3Division of Infectious Diseases, Kantonsspital St Gallen, St Gallen, Switzerland. 4Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland

<table>
<thead>
<tr>
<th></th>
<th>Value (95%CI)</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>Kappa coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dual-LAMP-Plasmodium spp. assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorimetric reading</td>
<td>95.4% (90.4%-100%)</td>
<td>96.3% (91.5%-100%)</td>
<td>96.5% (92.1%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorescence reading</td>
<td>96.5% (92.1%-100%)</td>
<td>97.5% (93.5%-100%)</td>
<td>97.7% (93.9%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual-LAMP-P. falciparum assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorimetric reading</td>
<td>100% (98.5%-100%)</td>
<td>100% (98.5%-100%)</td>
<td>100% (98.5%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorescence reading</td>
<td>100% (98.5%-100%)</td>
<td>100% (98.5%-100%)</td>
<td>100% (98.5%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual-LAMP-P. vivax assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorimetric reading</td>
<td>100% (98.5%-100%)</td>
<td>96.6% (88.2%-100%)</td>
<td>97.1% (90.2%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorescence reading</td>
<td>100% (98.5%-100%)</td>
<td>96.6% (88.2%-100%)</td>
<td>97.1% (90.2%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual-LAMP-P. ovale assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorimetric reading</td>
<td>90.5% (69.4%-100%)</td>
<td>100.0% (95.0%-100%)</td>
<td>100.0% (90.0%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorescence reading</td>
<td>90.5% (69.4%-100%)</td>
<td>100.0% (95.0%-100%)</td>
<td>100.0% (90.0%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual-LAMP-P. malariae assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorimetric reading</td>
<td>75.0% (20.1%-95.4%)</td>
<td>100.0% (90.0%-100%)</td>
<td>100.0% (83.3%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorescence reading</td>
<td>75.0% (20.1%-95.4%)</td>
<td>100.0% (90.0%-100%)</td>
<td>100.0% (83.3%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual-LAMP-P. knowlesi assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorimetric reading</td>
<td>83.3% (45.2%-100%)</td>
<td>100.0% (90.0%-100%)</td>
<td>100.0% (90.0%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluorescence reading</td>
<td>83.3% (45.2%-100%)</td>
<td>100.0% (90.0%-100%)</td>
<td>100.0% (90.0%-100%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A) Colorimetric result reading: yellow tubes indicate positive results; meanwhile pink tubes are negative results. B) Fluorescence result reading: fluorescence above the threshold are considered positive results, with the Ta as the minutes until fluorescence overtake the threshold.

Conclusions: This study outlines the ability of six Dual-LAMP assays for malaria diagnosis. Dual-LAMP-Psp assay with the addition of Dual-LAMP-RC assay and the possibility of a simple and fast purification provided low limit of detection and no cross-reactivity. Reagents lyophilisation plus the chance to read the results in two ways allow their application in many settings.

Funding: This work was supported by the Spanish Strategic Health Action [Grant number CM17CIII/00012]. Alexandra Martin Ramirez was supported by a grant from ISCIII-Rio Hortega [Grant number P17/CIII/0003].

39. MULTIPARAMETRIC CHARACTERIZATION OF TELOMERE LENGTH IN T CELLS FROM PLHIV BY FULL SPECTRUM FLOW-FISH

Macedonia Trigueros1, María Nevot1, Francisco Muñoz-López1, Ana Martínez2, Sandra Gonzalez4, Jordi Puig2, Coral Loste2, Patricia Echevarria1, Diana Hernández2, Marco A. Fernández3, Julíà Blanco1, Eugenia Negredo1, Marta Massanella1

1IrsiCaixa-AIDS Research Institute and Germans Trias i Pujol Health Research Institute, Badalona, Spain. 2Fundació Lluita contra les Infeccions, Germans Trias Pujol Health Research Institute, Badalona, Spain.
Spain. 1Flow Cytometry Facility, Germans Trias i Pujol Health Science Research Institute, Badalona, Spain.

Introduction: People living with HIV (PLWH) on antiretroviral therapy (ART) present higher prevalence of ageing-associated morbidities than uninfected individuals.

Objectives: We assessed markers of immunosenescence in CD4 and CD8 T cells from well clinically characterized older PLWH and HIV-negative individuals.

Methods: We included 27 PLWH on ART and 24 HIV-negative controls (HNC) from the OVER50 cohort. We performed a multiparametric flow-FISH technique on frozen PBMCs to simultaneously assess the relative telomere length (RTL) of T cells with a telomere-specific peptide nucleic acid probe by spectral flow cytometry, using 1301 cells as reference. We studied the frequency and RTL of CD4 and CD8 T cell subsets (CD45RA, CCR7, CD27, CD28 CD25, CD127), and activated (HLA-DR+CD38+), senescent (CD57+, KRLG1+) and exhausted (PD-1+) cells.

Results: PLWH were 85% males with a median age of 72 IQR [70-75] years and on suppressive ART for a median of 16 IQR [8-20] years. HNC were matched by age and gender (79% males, median age 73 IQR [69-75] years). Clinically, there were no significant differences in the number of comorbidities between PLWH and HNC (median 3.6 IQR [2-5] and 3.25 IQR [2-5], respectively). Only dyslipidemia was significantly higher in PLWH (70%) compared with uninfected group (17%, p < 0.01). The frequency of total CD4 T cells was lower in PLWH compared to HNC group (p < 0.01), while no major differences in the CD4 T-cell maturation subsets or T-regulatory cells were found. No differences were observed in the RTL in total or CD4 T cell subsets, except for transitional memory (TM, p = 0.09) and effector memory (p = 0.06) cells from PLWH, which tended to have shorter RTL than HNC. PLWH show higher frequencies of total CD8 T cells than HNC (p < 0.01), but CD8 T-cell distribution was similar between groups. We did not observe differences in RTL in total CD8 T cell between groups, whereas naïve (p = 0.06), central memory (CM, p = 0.03) and TM (p = 0.05) CD8 T cell subsets showed shorter RTL in PLWH compared to HNC. The frequencies of senescent, exhausted and activated CD4 and CD8 T cells were similar between groups, and no differences in the RTL in these subsets were observed.

Conclusions: Flow-FISH technique using full spectrum flow cytometry allowed a deep immune-characterization of the RTL in total and CD4 and CD8 T cell subsets from older PLWH and uninfected controls. Limited differences in RTL were observed between groups, suggesting similar immunoeageing status in older individuals independently of HIV serostatus.

Funding: Proyecto PID2020-114929RA-I00 financiado por MCIN/AEI/10.13039/501100011033 y por el FSE invierte en tu futuro. PERIS:SLT017/20/000095.

40. FORECASTING THE GEOGRAPHICAL DISTRIBUTION OF RISKY AREAS WEST NILE VIRUS IN SPAIN

Patricio Artigas1,2, Pablo Cuervo1,2,3, Santiago Mas-Coma1,2, María Cecilia Fantozzi1,2, María Dolores Bargues1,2

1Universitat de València, València, Spain. 1,2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), Instituto de Salud Carlos III, Madrid, Spain. 1Laboratorio de Ecología de Enfermedades, Instituto de Ciencias Veterinarias del Litoral (ICIVET–Litoral), Universidad Nacional del Litoral (UNL)/Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Esperanza, Argentina.

Introduction: West Nile virus (WNV), a well-known emerging vector-borne arbovirus with a zoonotic life cycle, represents a threat to both public and animal health. Transmitted by ornithophilic mosquitoes, its transmission is difficult to predict and even more difficult to prevent. The massive and unprecedented number of human cases and equid outbreaks in Spain during 2020 interpellates for new approaches.

Objectives: Provide an insight to the situation of West Nile Disease (WND) in Spain, from the perspective of the ecological niches defining the circulation of WNV and the presence of its main vectors.

Methods: Applying niche model techniques, we modelled the climatic conditions suitable for the circulation and occurrence of outbreaks of WND in Spain, as well as for the presence of its main vectors Culex pipiens and Culex perexiguus with molecular identification. A total of 19,710 models were calibrated. Each model was evaluated for statistical significance (partial ROC tests), performance (omission rate) and the Aikake Information Criterion corrected for small sample sizes (AICc). A map of climatic risk of transmission was constructed considering the overlapping areas of the 10th-percentile thresholded binary maps with low uncertainty, which delimited suitable areas for circulation of WNV and for the presence of its vectors.

Results: After spatial filtering and removal of duplicates, global occurrences were reduced to: 62 records of C. pipiens, 16 records of C. perexiguus and 105 outbreak records of WND in equids. Maps of the climatic suitability for the presence of the two vectors species and for the circulation of WNV are provided (Table). The main outcome of our study is a map delineating the areas under certain climatic risk of transmission. Our analyses indicate that the climatic risk of transmission of WND is medium in areas nearby the south Atlantic coastal area of the Cadiz Gulf and the Mediterranean coast, and high in southwestern Spain (Figure).

Table 1 Schematic representation of the criteria adopted to determine the climatic risk of transmission

<table>
<thead>
<tr>
<th>Risk</th>
<th>Presence of suitable conditions</th>
<th>West Nile</th>
<th>Culex pipiens</th>
<th>Culex perexiguus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very low</td>
<td>▼ absence; ▲ presence; ▲▲ presence with high</td>
<td>▼</td>
<td>▲▲</td>
<td>▲▲</td>
</tr>
<tr>
<td>Low</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>Medium</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
<tr>
<td>High</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
<td>▲</td>
</tr>
</tbody>
</table>

Note: ▲ absence; ▲ presence; ▲▲ presence with high; Suitability.

Map of climatic risk of transmission, constructed considering the binary maps after applying a 10th-percentile threshold and with low uncertainty.

Conclusions: The higher risk of transmission in the basins of the rivers Guadiana and Guadalquivir can- not be attributed exclusively to the local abundance of C. pipiens, but could be ascribed to the pres-
ence and abundance of *C. perexiguus*. Furthermore, this integrated analysis suggests that the WNV presents an ecological niche of its own, not fully overlapping the ones of its hosts or vector, and thus requiring particular environmental conditions to succeed in its infection cycle.

Funding: CIBER de Enfermedades Infecciosas, Grant/Award Number: CB21/13/00056 and IM22/INF/6; ISCIII, Ministry of Science and Innovation and European Union NextGenerationEU; Red de Investigación de Centros de Enfermedades Tropicales, Grant/Award Number: RD16/0027/0023; ISCIII-Subdirección General de Redes y Centros de Investigación Cooperativa RETICS, Ministry of Science and Innovation; PROMETEO Program, Programa de Ayudas para Grupos de Investigación de Excelencia, Generalitat Valenciana, Grant/Award Numbers: 2016/099, 2021/004.

45. IMMUNE RESPONSE IN SARS-COV-2 INFECTION

Elena Morte Romea1,2,3, Iratxe Uranga2,4, Sandra Hidalgo2, Ariel Ramírez-Labrada2,3, Diego de Miguel1, Eva Gálvez2,4, Luis Martínez lostao2,3, Galadriel Pellejero Sagastizábal1,2, Santiago Letona Jiménez2, Julián Pardo2,3,4, José Ramón Paño Pardo1,2,4
1Servicio de Enfermedades Infecciosas, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. 2Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain. 3Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFE), Madrid. 4Centro de Investigación Biomédica en Red (CIBER) en Enfermedades Infecciosas, Madrid, Spain. 5Unidad de nanotecnología e inmunología experimental (UNATI). Centro de Investigación Biomédica de Aragón, Zaragoza, Spain. 6Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain. 7Departamento de Inmunología, Pediatría, Radiología y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain. 8Departamento de Inmunología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Introduction: We analyzed several parameters of the immune response of COVID-19 patients who required hospital admission, comparing them to healthy donors (HDs) and other patients admitted for respiratory infections not caused by SARS-Cov-2 (non-COV-RTI). We focused on the main cells involved in innate immunity and soluble inflammatory factors that regulate their activity.

Objectives: The main objective was to characterize the immune profile of COVID-19 patients compared to HDs and non-COV-RTI patients. We aimed to identify useful patterns that differentiate COVID-19 from other infections and predict the severity and risk of death.

Methods: We screened patients admitted to Lozano Blesa Hospital for SARS-CoV-2 infection from April to May 2020. Patients with respiratory tract infection and negative tests for SARS-CoV-2 (PCR and serological test) were classified as non-COV-RTI. We classified COVID-19 patients into mild and moderate/severe groups according to the WHO score. Peripheral blood was collected from all participants within the first 24 hours after hospital admission before any treatment was prescribed and clinical data were compiled from the electronic medical record. We performed flow cytometry, multiplex plasma protein analyses and enzyme activity assays.

Results: We included 86 COVID-19 patients and 27 non-COV-RTI patients. Sex, age, number of days from symptoms onset to blood sampling and median length of hospital stay were not significantly different between the cohorts. COVID-19 patients, especially those in the moderate/severe group, had lower lymphocyte counts (794 cell/µL) and significantly longer hospital stays (mean of 17 and 6 days). Figure A represented the differences in cell populations. We observed a significant increase in the expression of both activation (CD38+HLA-DR+GzmBHigh) and exhaustion (TIM3+, LAG3+, PD1+) markers in CD8+ T cell population in COVID-19 patients compared to HDs. Similarly, we found a significant increase in activated (GzmBHighPD1, GzmBHighLAG3+, GzmBHighTIM3+) and exhausted (GzmBLowPD1+, GzmBLowLAG3+, GzmBLowTIM3) NKCD56Dim cells in COVID-19 compared to HD and non-COV-RTI. Regarding inflammatory cytokine and chemokine levels, we observed a general increase during COVID-19 in compared to HD (IL1B, IL31, IL33). Specifically, we consistently found elevated levels of IL18 and CXCL10 in COVID-19 patients, which were also related to the more severe group, as well as NKG2D soluble ligands and granymes.

Conclusions: We detected a high activation of CD8+ and NK cells, with an early expression of inhibitory checkpoints and NKG2D soluble ligands, but with the maintenance of the excretion of granymes and an aggressive production of mainly interleukins. This pattern is specific to Covid-19 patients when compared to HDs and non-COV-RTI. Funding: Instituto de Salud Carlos III (COV20/00308).

48. ANTIMICROBIAL PEPTIDES FOR PSEUDOMONAS AERUGINOSA COLONIZATION IN CYSTIC FIBROSIS: A MICROBIOLOGICAL APPROACH WITH MUREPAVADIN

José Avendaño-Ortiz1,2, Raquel Barbero-Herranz1, Marta Hernández-García1,2, Natalia Bastón-Paz1, María Díez-Aguilar1,2,3, Luna Ballesteron1, Blanca Pérez-Viso1, Eduardo López-Collazo4,5, Miquel B. Ekkelemenp6, Ad Fluitt6, Rosa del Campo1,2, Rafael Cantón1,2
1Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFE), Madrid, Spain. 3Servicio de Microbiología y Parasitología, Hospital Universitario La Princesa, Madrid, Spain. 4Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 5Innate immune response group, Madrid, Spain. 6Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Introduction: Colistin is a cationic antimicrobial peptide active against *Pseudomonas aeruginosa* (PA) colonization in people with cystic fibrosis (pwCF). Its resistance acquisition involves genetic alterations leading to lipopolysaccharide modifications and colistin resistance. Recently, murepavadin has been proposed as a topical inhaled antimicrobial peptide in pwCF by targeting PA-LPS transport (L-Ara4N) addition. PA adaptation to pwCF airway also involves inflammatory factors that regulate their activity.

Methods: We screened patients admitted to Lozano Blesa Hospital for SARS-CoV-2 infection from April to May 2020. Patients with respiratory tract infection and negative tests for SARS-CoV-2 (PCR and serological test) were classified as non-COV-RTI. We classified COVID-19 patients into mild and moderate/severe groups according to the WHO score. Peripheral blood was collected from all participants within the first 24 hours after hospital admission before any treatment was prescribed and clinical data were compiled from the electronic medical record. We performed flow cytometry, multiplex plasma protein analyses and enzyme activity assays.

Results: We included 86 COVID-19 patients and 27 non-COV-RTI patients. Sex, age, number of days from symptoms onset to blood sampling and median length of hospital stay were not significantly different between the cohorts. COVID-19 patients, especially those in the moderate/severe group, had lower lymphocyte counts (794 cell/µL) and significantly longer hospital stays (mean of 17 and 6 days). Figure A represented the differences in cell populations. We observed a significant increase in the expression of both activation (CD38+HLA-DR+GzmBHigh) and exhaustion (TIM3+, LAG3+, PD1+) markers in CD8+ T cell population in COVID-19 patients compared to HDs. Similarly, we found a significant increase in activated (GzmBHighPD1, GzmBHighLAG3+, GzmBHighTIM3+) and exhausted (GzmBLowPD1+, GzmBLowLAG3+, GzmBLowTIM3) NKCD56Dim cells in COVID-19 compared to HD and non-COV-RTI. Regarding inflammatory cytokine and chemokine levels, we observed a general increase during COVID-19 in compared to HD (IL1B, IL31, IL33). Specifically, we consistently found elevated levels of IL18 and CXCL10 in COVID-19 patients, which were also related to the more severe group, as well as NKG2D soluble ligands and granymes.

Conclusions: We detected a high activation of CD8+ and NK cells, with an early expression of inhibitory checkpoints and NKG2D soluble ligands, but with the maintenance of the excretion of granymes and an aggressive production of mainly interleukins. This pattern is specific to Covid-19 patients when compared to HDs and non-COV-RTI. Funding: Instituto de Salud Carlos III (COV20/00308).
(COLR, n = 15), 2) murepavadin-resistant (MURR, n = 116), 3) double-resistant (COLMRURR, n = 17), and 4) double-susceptible (COLSMURS, n = 349) according to EUCAST-2022 and ECOFFs (COL > 4 mg/L and MUR > 0.25 mg/L). Whole genome sequencing (Illumina Miseq), assembling (SPAdes), annotation (Prokka) and Genome-Wide Association Studies (GWAS) were performed. To study the immunogenic properties of lipid A, six strains were employed: one COLR, two COLS, and their three isogenic MURR mutants counterparts obtained in mutant prevention concentration assays. Lipid A was analyzed by negative-ionization mass-spectrometry. LPS was isolated, quantified, and used to study cytokine production and apoptosis by flow cytometry. Phagocytosis was evaluated by internalized bacteria count after monocytes infection at MOI (bacteria/monocyte ratio) of 10. Effects in bacterial growth of immune-derived peptides cathelicidin, indolicidin and β-defensin at 100 µg/mL were determined by 20-h OD600 monitoring.

Results: In the GWAS analysis, hisj and rsta variations were significantly associated with MURR. Regarding Lipid A, only COLR strains exhibited m/z 1577 and 1750 ions corresponding to L-Ara4N addition to penta-acylated and hexa-acylated lipid A. These modifications were not detected in COLS strains. MURR strains in contrast exhibited decreased relative abundance of the hexa-acylated m/z 1616 lipid A compared with their MURS counterparts. Regarding inflammatory response, we found overall low inflammatory cytokine production triggered by MURR LPS compared with MURS. Significant changes between murepavadin-susceptible and resistant strains were not found in apoptosis, neither phagocytosis. Cathelicidin and β-defensin resulted in slightly longer lag-phase in MURR.

Conclusions: GWAS revealed genetic variations associated to MURR. Decreased abundance in hexa-acylated Lipid A, but not L-Ara4N addition, were found in MURR strain possibly explaining their lower ability of inflammatory induction. Murepavadin-resistance did not translate to reduced host-antimicrobial peptide susceptibility, in contrast, it slightly increased.

Mean scores (95%CI) for each item and domain of the WHOLQOL-HIV-Bref.

Conclusions: Only 55.3% of PWH, mostly on ART and virally suppressed, reported good/very good HRQoL, and this percentage was even lower among those with an AIDS diagnosis. The most affected items were sexual satisfaction and sleep and rest. Funding: ISCIII-AESI2020.

52. DEVELOPMENT OF REAL TIME PCR TECHNIQUES TO IMPROVE THE DIAGNOSIS AND IDENTIFICATION OF THE EMERGING YEAST CANDIDA AURIS, CAUSING INTRA-HOSPITAL OUTBREAKS

Leticia Bernal Martínez1, Ana Cecilia Mesa Arango2, Laura de Francisco Abad3, Carolina Zapata Zapata4, Javier Pemán5, María José Buitrago6
Introduction: Candida auris is associated with nosocomial outbreaks and high mortality rates, both due to its extremely rapid propagation capacity, and due to the difficult to treat as it is a multi-resistant pathogen. For all these reasons, the WHO has recently included it as a critical fungal pathogen. Rapid detection and identification are essential, however, this species is often misidentified by common laboratory identification methods.

Objectives: To improve the diagnosis and identification of C. auris by the development of two rapid methods based on real time PCR: Monoplex-qPCR and Multiplex-qPCR, which allows the detection of the four most frequent Candida spp. in clinical setting and species resistant to antifungals. In addition, a method based on High Resolution Melting (HRM), for the rapid identification of a total of 6 Candida spp., including C. auris.

Methods: New primers and a probe targeting the ITS1 region were designed for the specific detection of C. auris by using Beacon Design 9.1 program (Premier Biosoft, USA). The reaction conditions were optimized. All the techniques were performed on the LC480II equipment (Roche, Madrid, Spain). DNA concentrations between 1 ng and 1 fg/µl were used. Sensitivity, specificity and reproducibility of the technique were determined with a total of 44 clinical strains (31 C. auris). For the HRM technique, ITS 3–4 primers were used, and DNA adjusted a 5 ng/µl. The clinical validation was carried out with exudate samples, from 18 patients admitted to the Hospital Universitario y Politécnico La Fe, Valencia.

Results: The techniques developed presented high sensitivity, and reproducibility, the detection limit was established between 100–1 fg/ul of sample and the coefficient of variation was 2.2%-3% respectively. Furthermore, no cross-reaction with other related species was detected. In the clinical validation, C. auris was detected in 17/18 samples, 100% sensitivity.

Conclusions: The techniques developed for the detection of C. auris turned out to be sensitive, specific, and reproducible for the diagnosis. The HRM technique can be considered a simple and fast method, it could be a simple tool to identify this emerging species. Results obtained are quite promising and it seem to indicate that these techniques could be implemented applied in the clinical setting. Further validation with a larger number of patient samples will be required.

Funding: This work was supported by the Instituto de Salud Carlos III: PI20CI/00012, PI21CI/00007, and CIBER INFEC CB21/13/00105.

53. MOLECULAR DETECTION OF RICKETTSIA SPP. IN WILD UNGULATES AND THEIR TICKS IN MEDITERRANEAN AREAS OF SOUTHWESTERN SPAIN

David Cano-Terriza12, Susana Remesar3, Patrocínio Morrondo1, Saúl Jiménez-Ruiz3, Ceferino M. López3, Débora Jiménez-Martín1, Pablo Díaz1, Jorge Paniagua1, Javier Caballero-Gómez12,4, Antonio Rivero-Juárez1,4, Ignacio García-Bocanegra12

Introduction: Wildlife is an important reservoir of zoonotic pathogens. Objectives: The objective of the present study was to assess the importance of wild ungulates in the epidemiology of Rickettsia spp. Methods: Ticks and spleen samples were collected from 262 red deer (Cervus elaphus) and 83 wild boar (Sus scrofa) hunted in southwestern Spain during the period 2016-2021. DNA was extracted from tick pools (n = 191) and spleens (n = 345) and Rickettsia DNA was detected using two nested PCR targeting the rOmpA and rOmpB genes.

Results: Five tick species were identified (Hyalomma lusitanicum, Dermacentor marginatus, Ixodes ricinus, Rhipicephalus bursa and Haemaphysalis sulcata). Rickettsia DNA was detected in 31 (16.2%) tick pools and two red deer spleen samples (0.8%). Four validated Rickettsia species (R. slovaca, R. monacensis, R. helvetica and R. raoultii), one uncharacterized species (Candidatus R. rioja) and two uncharacterized Rickettsia spp. were detected in ticks. Rickettsia helvetica and R. slovaca were also detected in spleen samples from red deer.

Conclusions: The overall prevalence in ungulate spleen samples was lower than in tick pools suggesting that these ungulates do not play a major role in the transmission of Rickettsia spp. However, their importance as spreaders of positive ticks cannot be ruled out. The results present a challenge for the veterinary and public health communities since most of the Rickettsia spp. detected are pathogenic. Furthermore, the new Rickettsia species could be potential pathogens. For these reasons, identifying Rickettsia species present in ticks and wildlife is of particular interest to clarify their sylvatic cycle and establish appropriate control measures.

Funding: This study is part of the TED2021-132599B-C22 project, funded by MCIN/AEI/10.13039/501100011033 and by the European Union “NextGenerationEU”/PRTR. Recovery, Transformation and Resilience Plan - Funded by the European Union – NextGenerationEU. It was also partially funded by the research project LifeWATCH INDALO - Scientific Infrastructures for Global Change Monitoring and Adaptation in Andalusia (LIFEWATCH-2019-04-AMA-01), financed with FEDER funds (POPE 2014-2020) and by CIBER - Consorcio Centro de Investigación Biomédica en Red - CB 2021, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU.

1Departamento de Sanidad Animal, Grupo de Investigación GISAZ, UIC Zoonosis and Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 3Investigación en Sanidad Animal: Galicia (Grupo INVESAGA), Facultad de Veterinaria, Universidad de Santiago de Compostela, Lugo, Spain. 4Grupo de Virología Clínica y Zoonosis, Unidad de Enfermedades Infecciosas, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Universidad de Córdoba, Córdoba, Spain.
57. ZOONOSIS SCREENING IN SPANISH IMMUNOCOMPROMISED CHILDREN AND THEIR PETS

Paula García1, David Romero Trancón1, Belén Pérez2, Jara Hurtado Gallego1,3, Rocío Sánchez2, Jorge Atucha4, Iker Falces1,6, David Carmena1, Antonio Rivero Juárez3,5,10, Antonio Rivero Román1,15, Paula Navarro Carrera1, Guillermo Ruiz Carrascoso1, Laura Moya1, Sonia Alcolea1,5,3, Cristina Calvo1,4,5,11, Talia Sainz4,14,15,16, Ana Méndez Echeverría1,4,16,17

1Hospital Infantil La Paz, Madrid, Spain. 2Centro de Investigación IdiPaz, Madrid, Spain. 3Centro de Enfermedades Infecciosas y de Enfermedades Respiratorias, Hospital La Paz, Madrid, Spain. 4Centro de Investigación Biomédica de Córdoba (CIBERED), Córdoba, Spain. 5Hospital Universitario Reina Sofía, Córdoba, Spain. 6Hospital Universitario La Paz, Madrid, Spain. 7Laboratorio de Infectious Diseases, Córdoba, Spain. 8Instituto Maimonides de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00025), Madrid, Spain. 9Instituto Maimonides de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00029), Hospital La Paz, Madrid, Spain. 10Universidad de Córdoba (UCO), Córdoba, Spain. 11Unit of Infectious Diseases, Hospital Universitario Reina Sofía, Córdoba, Spain. 12Hospital Universitario La Paz, Madrid, Spain. 13Hospital Universitario La Paz, Madrid, Spain. 14Hospital Universitario La Paz, Madrid, Spain. 15Instituto de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain. 16Universidad de Córdoba (UCO), Córdoba, Spain. 17Unit of Infectious Diseases, Hospital Universitario Reina Sofía, Córdoba, Spain.

Introduction: Pets provide health benefits for children, but the risk of zoonotic infections must be considered, especially among immunocompromised patients. A One Health perspective is essential for effective prevention and to provide evidence-based medical and veterinary recommendations.

Objectives: To determine the prevalence of colonization/infection by zoonotic microorganisms in immunocompromised children and their pets.

Methods: A prospective study in immunocompromised children from La Paz Hospital who have cats and/or dogs (2022-2023). Serologies were performed in patients and pets (according to host-related pathogens): Bartonella, Toxocara canis, Strongyloides, Toxoplasma gondii, Leishmania, Leptospira, Ehrlichia canis, Borrelia burgdorferi, Hepatitis E virus, Rickettsia, Babesia canis and Anaplasma. PCR for 16 protozoa and bacteria in faeces as well as for *Rocapheusirus* varti and *Paslahepeusirus* balayani were performed. Nasopharyngeal and rectal swabs were obtained in patients and pets to study bacterial colonisation (*Staphylococcus aureus*, *Staphylococcus pseudintermedius* and resistant enterobacteria*ceae colonization*). Sanger sequencing was used for species/genotypes identification when possible.

Results: We present preliminary results from an ongoing research study including 57 children and 68 pets. Up to 17% of faecal samples from pets were positive by PCR for one or more faecal microorganisms including *Enterocytotoxan bieneusi* (4.5%; 3/67), *Campylobacter jejuni* (4.4%; 3/68), *Giardia* spp. (3%; 2/68), *Paslahepeusirus balayani* genotype 3 (HEV-3) (2.6%; 1/38), *Cryptosporidium* spp. (1.4%; 1/68) and *Blastocystis* sp. (1.4%; 1/68). Among children, gastrointestinal pathogens were found in 31% of the patients: HEV-3 (9%; 2/21), *Giardia intestina*lis (6.6%; 3/45), *Cryptosporidium* spp. (3.3%; 2/46), *Blastocystis* sp. (2%; 1/46), *C. jejuni* (2.2%; 1/46) and *Yersinia enterocolitica* (2.2%; 1/46). We found positive serologies among children for *Bartonella* spp. (17%; 3/17), *Strongyloides* spp. (8.1%; 4/49), *Toxocara* spp. (4%; 2/49) and *HEV* (3.5%; 2/57). Colonization by *S. pseudintermedius* was common among dogs (10.6%; 7/66), but not among children (0%). Two patients were colonised by *K. pneumoniae* OXA–48 and ESBLs *K. pneumoniae* (3.4%). No other colonizations were detected. Until the date, we have no identified shared colonisations/infections between pets and owners, although samples are still being collected and analysed. Results from pet’s serology and faeces studies such as coproantigen diagnostic im-

munoassay, microscopy following centrifugal flotation and PCR for hookworms, whipworms and ascarids are currently undergoing.

Conclusions: Although preliminary, our results indicate that a non-negligible percentage of dogs/cats living with immunocompro-
mised children are colonized/infected by potentially zoonotic agents. Although no events of zoonotic transmission could be identified, the role of infected animals as potential reservoirs of human infections cannot be overlooked, as suggested by the finding.

Funding: Spanish Pediatrics Association (AEP) 2021 Research Grant and MAPFRE Foundation Research grants “by Ignacio H. de Larramen-
di 2021”.

63. BACTEREMIA AS AN INDICATOR OF QUALITY OF CARE IN ELDERLY PATIENTS

Martha Kestler, Patricia Muñoz, Carlos Sanchez, Luis Alcalá, Rodrigo Valdivinos, Jose Antonio Serra, Emilio Bouza
Gregorio Marañón University Hospital, Madrid, Spain.

Introduction: The incidence and origin of blood stream infections (BSI) in patients over 80 years of age is not well known. Of particular interest is the knowledge of episodes of hospital onset bacteremia (HOB), as this figure is currently proposed as an indicator of quality of care.

Objectives: To know the real incidence of BSI in the elderly population, with particular interest in the place of origin, aetiology and clinical outcome.

Methods: Observational study, from January to June 2021, in a large tertiary Spanish centre; in which all BSI in patients over 80 years of age were prospectively recorded.

Results: During study period, a total of 624 patients suffered one or more episodes of significant bacteremia. Of these, 147 patients were

General characteristics of 147 BSI in patients over 80 years old, according to acquisition

<table>
<thead>
<tr>
<th>Sex</th>
<th>Community</th>
<th>Health Care Related</th>
<th>Nosocomial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>47 (55.3%)</td>
<td>10 (58.8%)</td>
<td>25 (55.6%)</td>
</tr>
<tr>
<td>Origen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catheter Related</td>
<td>0 (0%)</td>
<td>1 (5.9%)</td>
<td>21 (46.7%)</td>
</tr>
<tr>
<td>Urinary Tract</td>
<td>31 (36.5%)</td>
<td>9 (52.9%)</td>
<td>12 (26.7%)</td>
</tr>
<tr>
<td>Abdominal</td>
<td>33 (38.8%)</td>
<td>1 (5.9%)</td>
<td>5 (11.1%)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>1 (12%)</td>
<td>3 (17.6%)</td>
<td>2 (4.4%)</td>
</tr>
<tr>
<td>Skin and Soft tissue</td>
<td>7 (8.2%)</td>
<td>1 (5.9%)</td>
<td>1 (2.2%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>6 (7%)</td>
<td>1 (5.9%)</td>
<td>4 (8.9%)</td>
</tr>
<tr>
<td>Aetiology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gram Positives</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S. aureus</td>
<td>7 (8.3%)</td>
<td>3 (17.6%)</td>
<td>7 (15.6%)</td>
</tr>
<tr>
<td>SAMS</td>
<td>5 (5.9%)</td>
<td>0</td>
<td>4 (8.9%)</td>
</tr>
<tr>
<td>SAMR</td>
<td>2 (2.4%)</td>
<td>3 (17.6%)</td>
<td>3 (6.7%)</td>
</tr>
<tr>
<td>Enterococci</td>
<td>3 (3.6%)</td>
<td>0 (0%)</td>
<td>8 (17.8%)</td>
</tr>
<tr>
<td>E. faecalis</td>
<td>2 (2.4%)</td>
<td>-</td>
<td>5 (11.1%)</td>
</tr>
<tr>
<td>E. faecium</td>
<td>1 (1.2%)</td>
<td>-</td>
<td>3 (6.7%)</td>
</tr>
<tr>
<td>Gram Negatives</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. coli</td>
<td>39 (44.7%)</td>
<td>4 (23.5%)</td>
<td>4 (8.9%)</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>3 (3.5%)</td>
<td>1 (5.9%)</td>
<td>5 (11.5%)</td>
</tr>
<tr>
<td>Klebsiella spp</td>
<td>5 (5.9%)</td>
<td>20 (49.4%)</td>
<td>3 (6.7%)</td>
</tr>
<tr>
<td>BLEE</td>
<td>1 (1.2%)</td>
<td>20 (49.4%)</td>
<td>1 (2.2%)</td>
</tr>
<tr>
<td>Fungi</td>
<td>1 (1.2%)</td>
<td>0 (0%)</td>
<td>4 (8.9%)</td>
</tr>
<tr>
<td>Caudalidee spp</td>
<td>1 (1.2%)</td>
<td>0 (0%)</td>
<td>4 (8.9%)</td>
</tr>
<tr>
<td>Clinical Outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality during admission</td>
<td>16 (18.8%)</td>
<td>5 (20.4%)</td>
<td>14 (31.1%)</td>
</tr>
</tbody>
</table>
over 80 years of age and 477 under 80 years of age. The incidence of bacteraemia per 1,000 admissions in the population under and over 80 years of age was 26.57 and 37.81/1,000 admissions, respectively. Of the 147 BSI patients over 80 years old, episodes were community-acquired in 85 cases (57.8%), health-care-related in 17 (11.6%) and 45 (30.6%) suffered bacteraemia of Hospital Onset (HOB). Of the HOB episodes, 21 (46.7%) originated from vascular catheters (CR-BSI) and 12 (26.7%) from the urinary system in catheterised patients (CAUTI), 5 (11.1%) were of intra-abdominal origin, 2 (4.4%) of respiratory origin, 1 (2.2%) originated in a skin and soft tissue infection and 4 (8.9%) were of unknown origin. The aetiology of the HOB episodes had a predominance of Gram-positives (Enterococcus spp 9, S. aureus 7, other Staphylococci 9). Among the Gram negatives, the most frequent isolates were Pseudomonas aeruginosa 5, and E. coli 4. The mortality of bacteraemia during admission detected in those over 80 years of age was 35/147 (23.8%), and by place of acquisition was as follows: Community-acquired 16/85 (18.8 %), Health -Care Related 5/17 (29.4%) and HOB 14/45 (31.1%). After examination of the HOB episodes, 33/45 (73%) were, in the authors’ opinion, potentially avoidable.

**Conclusions:** HOB surveillance in the elderly, could be an easy to obtain, easy to follow, metric of infection control in these population. Episodes of HOB in the elderly must be considered failures of proper care and reviewed accordingly.

---

### 66. LONGITUDINAL STUDY OF CD4+ T CELLS POLARIZATION IN INDIVIDUALS WITH LONG-COVID SHOWS A PERSISTENT INCREASE IN PRO-INFLAMMATORY POPULATIONS AND A DECREASE IN ANTIVIRAL RESPONSE

Olivia de la Calle-Jiménez1,2, Clara Sánchez-Menéndez11, María Aránzazu Murciano-Antón1, Alicia Simón Rueda1,5, Guiomar Casado1, Elena Mateos16, Susana Domínguez-Mateos1, Esther San José1, Montserrat Torres15, María Teresa Coiras1,6

1AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain. 2Faculty of Sciences, Universidad Europea de Madrid, Madrid, Spain. 3Hematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Madrid, Spain. 4Family Medicine, Centro de Salud Doctor Pedro Lain Entralgo, Madrid, Spain. 5Faculty of Sciences, Universidad Complutense de Madrid, Madrid, Spain. 6Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.

**Introduction:** Persistent COVID-19 syndrome or Long-COVID is characterized by immunological alterations that seem to be related to chronic inflammatory responses. Affected individuals show high levels of cytotoxic cell populations which do not develop effective antiviral activity.

**Objectives:** In this study, we have analyzed the polarizing ability of CD4+ T lymphocytes in people diagnosed with Long-COVID, compared to individuals who fully recovered from COVID-19.

**Methods:** Longitudinal study with 28 individuals diagnosed with Long-COVID-19 49 weeks after SARS-CoV-2 infection and 13 individuals fully recovered from COVID-19 in the first 12 weeks after infection. Peripheral blood samples were collected at baseline and after 6 months. Polarization of CD4+ T lymphocytes was analyzed by flow cytometry, evaluating the surface expression of markers of different Th subpopulations: Th1, Th2, Th9, Th17, and Th22. Intracytoplasmic cytokine analysis was performed by specific ELISAs. Results: 1) Median age of individuals fully recovered from COVID-19 was 45 years (IQR 36-59) of which most were women (54%). Participants diagnosed with Long-COVID had a median age of 44 years (IQR 39.25-48.75) and 93% were women. 2) CD4+ Th1 lymphocytes levels were significantly reduced in participants with Long-COVID (-1.3-fold; p = 0.0217), compared to recovered participants. This decrease remained after 6 months (-1.3-fold; p = 0.0301). No changes in the ability of Th1 cells to produce IFNγ in response to SARS-CoV-2 were observed. 3) Levels of CD4+ Th9 and Th17 lymphocytes, highly pro-inflammatory, were significantly increased in Long-COVID participants (1.9-fold; p = 0.0005 and 2.2-fold; p < 0.0001, respectively). These levels were still increased after 6 months. IL-9 production by Th9 was significantly decreased in people with Long-COVID (-2.2-fold; p = 0.0357), even after 6 months. 4) No significant changes were observed in CD4+ Th2 and Th22 levels between both groups. However, there were increased numbers of IL-4 production by Th2 cells in Long-COVID patients (1.7-fold; p = 0.0107) which continued to increase after 6 months, while IL-13 production by Th22 was decreased 4.0-fold (p = 0.0002) and maintained after 6 months. No changes in IL-22 production by Th22 were observed in response to SARS-CoV-2.

**Conclusions:** CD4+ T lymphocytes from people with Long-COVID show significant changes in Th subpopulations, with a reduction in Th1 cells capable of polarizing the immune response towards an effective antiviral response, as well as an increase in pro-inflammatory Th9 and Th17 subpopulations. These changes in the levels of Th subpopulations were maintained after 6 months, which supports the persistence of immunopathological aspects in people with Long-COVID.

Funding: This work was supported by project PI22CII/00559, funded by the Strategic Action in Health of the Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (ERDF), “A way to make Europe”.

---

### 71. A NOVEL OPTIMIZED VACCINE CANDIDATE, MVA-COV2-S(3P), COMPLETELY PROTECT MICE AND HAMSTERS AGAINST SARS-COV-2 INFECTION WITH SEVERAL VARIANTS OF CONCERN

Patricia Pérez1,2, David Astorgano1, Guillermo Albericio1, Raúl Abdelnabi1, Kai Dellmeier1, Mariano Esteban1, Juan Francisco García-Arraza1,2

1Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 3KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology, Molecular Vaccinology and Vaccine Discovery, Leuven, Belgium.

**Introduction:** Development of optimized vaccines against COVID-19 capable of preventing the spread of SARS-CoV-2 and different variants of concern (VoCs) is necessary. Most COVID-19 vaccines are based on the SARS-CoV-2 spike (S) protein, the main target of neutralizing antibodies (NAbS). The prefusion state of the S protein is the most suitable immunogen for the development of better vaccine candidates, as it preserves the conformation of the S trimer, facilitating the induction of NAbS.

**Objectives:** We generated an optimized COVID-19 vaccine candidate based on the modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 S protein, termed MVA-CoV2-S(3P), to enhance the S-specific immune responses and achieve protection against SARS-CoV-2 infection, through different immunization routes and against different VoCs.

**Methods:** We evaluated the immunogenicity and efficacy of MVA-CoV2-S(3P) in animal models. First, we assessed in mice (immuno-competent C57BL/6 and transgenic K18-hACE2 mice) the immunogenicity and efficacy against ancestral Wuhan-1 strain and against beta and omicron VoCs when MVA-CoV2-S(3P) was administered by intramuscular and intranasal routes. On the other hand, we studied the efficacy in hamsters, as an alternative animal model.
Results: One single intramuscular or intranasal dose of MVA-CoV2-S(3P) induced high titers of systemic IgGs and Nabs against parental SARS-CoV-2 and several VoCs in C57BL/6 and K18-hACE2 mice. Moreover, one single intranasal dose of MVA-CoV2-S(3P) also induced in C57BL/6 mice mucosal S-specific IgA antibodies. Remarkably, one single intramuscular or intranasal administration of MVA-CoV2-S(3P) fully protected K18-hACE2 mice from SARS-CoV-2 (Wuhan strain) morbidity and mortality, reducing viral loads, histopathological lesions, and levels of pro-inflammatory cytokines in the lungs. Similar results were observed when MVA-CoV2-S(3P)-vaccinated K18-hACE2 mice were challenged with SARS-CoV-2 VoCs beta and omicron. Furthermore, one or two intramuscular doses of MVA-CoV2-S(3P) protected hamsters against SARS-CoV-2 infection, with induction of high titers of binding IgGs and Nabs, and reduction in viral loads in lungs and nasal washes, lung histopathological lesions, and levels of pro-inflammatory cytokines in the lungs.

Conclusions: The potent immunogenicity and full efficacy against different VoCs triggered by the optimized MVA-CoV2-S(3P) vaccine candidate in different animal models support its use as a COVID-19 vaccine in clinical trials.

Funding: Fondo COVID-19 grant COV20/00151 (ISCIII), Fondo Supera COVID-19 grant (Cruce Universidades-Banco Santander), CSIC grant 202120E079, and funds from CIBERINFEC co-financed with FEDER funds (to JG-A). CSIC grant 2020E84 (to ME). A MCIN/AEI/10.13039/501100011033 grant (P1D2020-114481RB-I00) and EC-Next Generation EU through CSIC’s PTI Salud Global (to JG-A and ME).

72. T-CELL IMMUNITY AGAINST SARS-COV-2 IS STRONGLY ASSOCIATED WITH PATIENT OUTCOMES IN VACCINATED PERSONS HOSPITALIZED WITH DELTA OR OMICRON VARIANTS

Marta Fernández González1,2, Vanesa Agulló1,2, José Alberto García1,2, Sergio Padilla1,2,3, Javier García Abellán1,2,3, Alba de la Rica1,2, Paula Mascarrell1, Mar Masía1,2,3, Félix Gutiérrez1,2,3

1Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 3Clinical Medicine Department, Universidad Miguel Hernández, San Juan de Alicante, Spain. 4Microbiology Service, Hospital General Universitario de Elche, Elche, Spain.

Introduction: Understanding protective immunity against SARS-CoV-2 after COVID-19 vaccination may be important for predicting the risk of severe breakthrough infections. While neutralising antibodies have been associated with protection from reinfection and severe COVID-19, little is known about the protective role of pre-existing cellular immunity to SARS-CoV-2.

Objectives: We measured T-cell and antibody responses to SARS-CoV-2 in vaccinated patients hospitalized for COVID-19, and explored their potential value to predict outcomes.

Methods: Prospective, longitudinal study including fully vaccinated patients hospitalized for COVID-19 caused by Delta and Omicron variants between July 22, 2021, and April 23, 2022. We measured TrimericS-IgG antibodies (DiaSorin) and SARS-CoV-2 T-cell response using a specific quantitative interferon-γ release assay (IGRA, Euromimmun) at hospital admission. Primary outcome was all-cause 28-day mortality or need for intensive care unit (ICU) admission. Secondary outcomes were 28–60- and 90-day mortality. Multivariable Cox-proportional hazards regression models were used to assess associations of immune responses with outcomes.

Results: 158 (87.3%) of 181 subjects meeting the eligibility criteria had detectable SARS-CoV-2 antibodies, 92 (50.8%) showed specific T-cell responses, and 87 (48.1%) had both antibodies and T-cell responses. Patients who died within 28 days or needed ICU admission were less likely to have unspecific interferon-γ release and SARS-CoV-2 specific T-cell responses, and had quantitatively lower interferon-γ responses in IGRA. In the adjusted analyses, having both T-cell and antibody responses at admission (aHR, 0.17; 95%CI, 0.05-0.61) and Omicron variant (aHR, 0.38; 95%CI, 0.17-0.87) reduced the hazard of 28-day mortality or ICU, whereas higher Charlson comorbidity index (aHR, 1.27; 95%CI, 1.07-1.51) and lower SpO2/FIO2 (aHR, 2.33; 95%CI, 1.49-3.65) increased the risk (Figure). Similar trends were observed for secondary outcomes.

Conclusions: Pre-existing immunity against SARS-CoV-2 is strongly associated with patient outcomes in vaccinated subjects requiring hospital admission for COVID-19. Persons showing both T-cell and antibody responses have the lowest risk of severe outcomes.

Funding: This research was supported by CIBER (CIBER21/13/00011), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU, and the Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital of Generalitat Valenciana (AICO/2021/205).

75. POINT-OF-CARE (POC) BIOSENSOR DEVICE FOR THERAPEUTIC DRUG MONITORING (TDM) OF ANTIMICROBIALS

Alejandro Astua1, Judith Poblet1, Luisa Sorlí2, Sònia Luque2, M. Carmen Estevez1, Milagro Montero3, Santiago Grau2, Juan-Pablo Horcajada2, Laura M. Lechuga1

1Catalan Institute of Nanoscience and Nanotechnology (ICN2), Barcelona, Spain. 2Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain.

Introduction: New diagnostic tools for the efficient use of antibiotics to increase clinical success and reduce the occurrence of adverse events and antimicrobial resistance are needed. These diagnostic systems should be easy to use and offer rapid results in order to perform a POC instantaneous therapeutic drug monitoring.

Objectives: To develop a POC portable optical biosensor for the rapid quantification and monitoring of two narrow-range antibiotics of interest (aminoglycans and colistin) as innovative tool for therapeutic drug monitoring (TDM) in decentralized settings at the point-of-care.

Methods: The new diagnostic technology is based on a Superficial Plasmon Resonance (SPR) biosensor setup and implements a one-step direct competitive immunoassay employing antibodies as bioreceptors. The biosensor is integrated in a compact and user-friendly platform for POC testing. The assay is fully optimized and allows the direct detection in serum samples with a time of analysis of less than 20 min. To assess the accuracy and feasibility of the biosensor test, quantification of antibiotic levels was made in 10 spiked serum samples (5 with amikacin and 5 with colistin) with known antibiotic concentrations.
Results: The accuracy of the immunosensor was higher than 90% for measuring the amikacin concentration in four of the five spiked samples, in which it was 74.4%. In the case of colistin in three samples the accuracy was about 90%, but in two it was less than 35%. For amikacin, the limit of detection (LOD) in the calibration curves was 0.14 ± 0.09 ng/ml (buffer) and 2.07 ± 0.13 ng/ml (serum 1/10), and for colistin, it was 9.4 ± 3.6 pg/ml (buffer) and 41.1 ± 0.9 pg/ml (serum 1/1000).

Conclusions: Competitive immunoassays for direct, one-step detection and quantification of amikacin and colistin quantification antibodies have been developed employing a portable SPR biosensor. The optimized assay reaches excellent levels of sensitivity, enabling the detection of both antibiotics in serum samples with better results for amikacin in this series. On-going work is focused on finalizing the colistin assay (accuracy analyses with spike samples) and a clinical validation study (prospective observational study) for amikacin and colistin quantification using real samples from hospitalized patients at Parc de Salut Mar, Barcelona, is about to start the patient’s inclusions. Funding: Alejandro Astúa acknowledges financial support from European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie grant agreement No. 754397. Judith Poblet has a pre-doctoral contract from CIBERINFEC. Instituto de Salud Carlos III. We acknowledge the financial support from PHITBAC project (PLEC2021-007739) funded by the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) and European Union NextGenerationEU/PRTR.

77. NANOBODY BASED IMMUNOTHERAPY FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS

Diego Sánchez-Martínez1, Sergio Redrado2, Elena Dolader-Ballesteros3, Javier Macías4, María Pilar Domingo1, Patricia Esteban1, Maykel Arias2, Ariel Ramírez2, Ramon Hurtado1, Julián Pardo1,2, Eva María Galván1,3

1Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Zaragoza, Spain. 3Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain. 4Departamento de Microbiología, Pediatría, Radiología y Salud Pública, Área de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Introduction: We aimed to identify potential immunological markers that differentiate individuals susceptible to SARS-CoV-2 infection from healthcare workers exhibiting resistance to the disease.

Methods: We included 26 ‘susceptible’ patients who provided blood samples within the first 7 days from the onset of symptoms and diagnosed SARS-CoV-2 infection by PCR from nasopharyngeal swabs, and 38 unvaccinated ‘non-susceptible’ healthcare workers on duty for at least three months in COVID-19 wards or intensive care units. Non-susceptible participants were asymptomatic and reported at least three high-risk exposures to SARS-CoV-2 without having experienced symptoms suggestive of SARS-CoV-2 infection. They were also persistently negative for SARS-CoV-2 PCR testing and did not have SARS-CoV-2 IgM and IgG in plasma. We extensively characterized phenotypically and functionally leukocyte subsets (including T and B cells, monocytes, NK and dendritic cells) by Flow Cytometry, acquired in a FACSCanto II flow cytometer (BD Biosciences). For data analysis, we used FACSDIVA software V.9.0 (BD Biosciences) and GraphPad Prism 8.0 software.

Introduction: The mechanisms driving SARS-CoV-2 susceptibility remain poorly understood, especially the immunological hallmarks determining why a subset of unvaccinated individuals remained uninfected despite high-risk exposures during the first pandemic waves.

Objectives: We aimed to identify potential immunological markers that differentiate individuals susceptible to SARS-CoV-2 infection from healthcare workers exhibiting resistance to the disease.

Methods: We included 26 ‘susceptible’ patients who provided blood samples within the first 7 days from the onset of symptoms and diagnosed SARS-CoV-2 infection by PCR from nasopharyngeal swabs, and 38 unvaccinated ‘non-susceptible’ healthcare workers on duty for at least three months in COVID-19 wards or intensive care units. Non-susceptible participants were asymptomatic and reported at least three high-risk exposures to SARS-CoV-2 without having experienced symptoms suggestive of SARS-CoV-2 infection. They were also persistently negative for SARS-CoV-2 PCR testing and did not have SARS-CoV-2 IgM and IgG in plasma. We extensively characterized phenotypically and functionally leukocyte subsets (including T and B cells, monocytes, NK and dendritic cells) by Flow Cytometry, acquired in a FACSCanto II flow cytometer (BD Biosciences). For data analysis, we used FACSDIVA software V.9.0 (BD Biosciences) and GraphPad Prism 8.0 software.

Conclusions: We have a developed a new Nb targeting essential fungal enzymes as an efficient alternative to treat invasive fungal infections and overcome increasing antifungal drug resistance. This new antifungal immunotherapy could contribute to reduce morbidity and mortality of a high number of patients at risk of these infections including cancer, ICU and transplantation. In addition, we provide the basis to develop other immunotherapies treatments based on Nb3 (Nb3-based CAR cells, bispecific nanobodies) increasing the armoury to fight these lethal fungal infections.

Funding: Gobierno de Aragón, Group B29_20R LMP139_21, FEDER (Fondo Europeo de Desarrollo Regional) Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (PID2020-113963RB-I00) CIBERINFEC, Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación y Unión Europea-NextGenerationEU.

Introduction: The invasive fungal infections ratios of mortality are between 25% and 70% depending on the type of microorganism and the population at risk, affecting mostly immunocompromised patients. Aspergillus spp. and Cryptococcus spp. are two of the main responsible for these infections. The late non-specific diagnosis and the increasing resistance of the strains highlight the importance of finding new therapeutic alternatives.

Objectives: Generate and validate a new nanobody (Nb3) targeting β-1,3-glucanosyltransferase, Gel, a key fungal enzyme involved in cell wall remodeling, that has been described as essential for fungal survival.

Methods: A. fumigatus and C. neoformans fungal growth was analysed by XTT reduction assay in RPMI 1640 medium with HEPES 20 mM. Cell wall sugar content of C. neoformans cultures treated and non-treated with Nb3 were analysed by HPLC. BALB/c mice were immunosuppressed with cyclophosphamide and/or hydrocortisone, infected and treated with Nb3. Survival, fungal load and Nb3 concentration were analyse.

Results: We have found that Nb3 exerts fungistatic activity in vitro against Aspergillus fumigatus and Cryptococcus neoformans, including antifungal resistant strains, which correlates with the localisation of Nb3 in the fungal cell wall where Gel enzyme is expressed. Moreover, treatment of fungus with Nb3 alters cell wall polysaccharide composition confirming enzyme inactivation in vitro. Using in vivo mouse models of Aspergillus and Cryptococcus infections we show that therapeutic administration of Nb3 in infected animals is highly effective and significantly increases animal survival, correlating with a reduction of fungal burden in lung and brain. Importantly, in vivo biodistribution analysis shows that Nb3 is able to cross the blood-brain barrier reaching the brain, main tissue affected during cryptococcosis.

Conclusions: Competitive immunoassays for direct, one-step detection and quantification of amikacin and colistin quantification antibodies have been developed employing a portable SPR biosensor. The optimized assay reaches excellent levels of sensitivity, enabling the detection of both antibiotics in serum samples with better results for amikacin in this series. On-going work is focused on finalizing the colistin assay (accuracy analyses with spike samples) and a clinical validation study (prospective observational study) for amikacin and colistin quantification using real samples from hospitalized patients at Parc de Salut Mar, Barcelona, is about to start the patient’s inclusions. Funding: Alejandro Astúa acknowledges financial support from European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie grant agreement No. 754397. Judith Poblet has a pre-doctoral contract from CIBERINFEC. Instituto de Salud Carlos III. We acknowledge the financial support from PHITBAC project (PLEC2021-007739) funded by the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) and European Union NextGenerationEU/PRTR.
Results: Susceptible patients exhibited a marked expansion of plasmablasts—a B cell subset responsible of the production of neutralizing antibodies, which can also contribute to dysregulated immune responses in some viral infections-, which directly correlated with the disease severity. In contrast, non-susceptible individuals consistently showed low proportions of plasmablasts and greater proportions of plasmacytoid dendritic cells (pDCs) -which can produce high concentrations of interferons when activated by viral antigens-. In addition, in susceptible patients, the percentage of CD56bright NK cells -a subset particularly relevant for the innate response against viral infections- was lower than in non-susceptible individuals. In contrast, NK cells expressing perforin and granzyme -driving responses able to eliminate virus-infected cells by inducing apoptosis- were increased in susceptible patients (Figure).

Conclusions: We found several immunological hallmarks of SARS-CoV-2 infection. The plasmablast expansion during the early phase of SARS-CoV-2 compared to the lower levels in healthcare workers repeatedly exposed may indicate a dysregulated immune response. Strong pDCs and CD56brightNK responses, two relevant actors of the antiviral immune response, could explain protection against SARS-CoV-2 infection.

Introduction: The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to major health, economic and social problems worldwide. The COVID-19 morbidity and mortality have been significantly reduced during these years thanks to the rapid approval and massive administration of effective vaccines against SARS-CoV-2, mainly targeting the surface-exposed spike glycoprotein (S). However, the emergence of new SARS-CoV-2 variants with enhanced transmissibility has impaired their efficacy. Therefore, it is desirable to design new vaccine candidates targeting other viral antigens to induce broad and long-lasting immunity with potential to counteract viral evolution and future outbreaks.

Methods: Viral patches included in the CoV2-BMEP synthetic protein were selected by manual sequence inspection of major dominant and persistent antigenic domains containing B and T cell epitopes recently recognized by SARS-CoV and SARS-CoV-2 survivors during natural infection and conserved across human endemic coronaviruses (HCoVs). The synthetic gene was inserted by homologous recombination into the MVA genome to generate MVA-CoV2-BMEP recombinant virus that was characterized in cultured cells and evaluated in mice for immunogenicity and efficacy.

Results: The multi-patch CoV2-BMEP protein was successfully expressed at high levels and in stable manner in MVA-CoV2-BMEP infected cells and was recognized by PBMCs from COVID-19 convalescent patients in vitro. In C57BL/6 mice, homologous prime/boost MVA/MVA immunization regimen induced broad SARS-CoV-2-specific T cells in lung and spleen as well as binding (bAbs) and neutralizing (NAbs) antibodies against S and N proteins, while in susceptible k18-hACE2-Tg model this protocol partially protected vaccinated mice from SARS-CoV-2 infection. The protection correlates with the levels of NAbs detected before the virus challenge.

Conclusions: In conclusion, the multi-patch CoV2-BMEP protein represents a novel immunogen with the capacity to control SARS-CoV-2 infection by inducing broad and cross-reactive B and T cell responses, and opens the field for improvements on this type of platform with potential for universal pan-coronavirus vaccine development.

Funding: This research was supported by CIBERINFEC (CB21/13/00108) and the MCIN (PID2020-117425RB-C22).
### 81. ASSOCIATION BETWEEN TELOMERE LENGTH IN COVID-19 PATIENTS AND RESPIRATORY PROGRESSION

**Ana Virseda Berdices**1,2, Óscar Martínez Gómez1, Celia Crespo Bermejo1, Óscar Brochado Kith1,2, Blanca López Matamala1, Carmen Martín Parra1, María Ángeles Alonso Fernández1, Miriam Chana García1, Sandra Sánchez López1, Madian Manso Álvarez2, Salvador Resino1,2, Rafael Blancas Gómez Casero1, María Ángeles Jimenez Sousa1,2, Amanda Fernández Rodríguez1,2

1Centro Nacional de Microbiología, Majadahonda, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 3Hospital Universitario del Tajo, Aranjuez, Spain.

**Introduction:** Telomere shortening is associated with an impairment of the immune system, which is explained by the progressive decline in physiological homeostasis associated with aging. The severity of acute respiratory distress syndrome (ARDS) depends on the amount of etiologic substances with corresponding immune reactions, the duration of the appearance of specific immune cells, or the repertoire of specific immune cells that control the substances.

**Objectives:** To study the impact of telomere length in whole blood from COVID-19 patients at disease onset for the need for invasive and non-invasive mechanical ventilation, the need for pronation, days of pronation and the worst PaO2/FiO2 in patients admitted to the ICU.

**Methods:** A cross-sectional prospective study enrolling critical non-vaccinated patients with COVID-19 recruited at Tajo University Hospital was carried out from March 2020 to April 2021. Blood samples were obtained upon admission to the ICU, prior to connection to mechanical ventilation. Relative telomere length (RTL) quantification was carried out using monochromatic multiplex real-time quantitative PCR (MMqPCR). The association analysis between RTL and several clinical variables was performed by generalized linear models (GLM), with binomial and gamma distribution, and adjusting for age, gender and BMI.

**Results:** Seventy-one unvaccinated COVID-19 patients were included in the study. The Table presents descriptive information of demographic and clinical characteristics. Initially, no association was found between RTL and the need for invasive mechanical ventilation (IMV) (OR 2.64; p-value = 0.155). However, after adjusting for age, gender and BMI, association becomes significant. Thus, patients who required invasive mechanical ventilation had a shorter RTL at disease onset than those who did not (Figure), with an OR = 13.70 (p-value = 0.019). No significant associations were found with the need for non-invasive mechanical ventilation, pronation, days of pronation and the worst PaO2/FiO2.

<table>
<thead>
<tr>
<th>All</th>
<th>No IMV</th>
<th>IMV</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>71</td>
<td>15</td>
<td>56</td>
</tr>
<tr>
<td>Age (years)</td>
<td>63.00</td>
<td>57.00</td>
<td>64.00</td>
</tr>
<tr>
<td>[54.00-70.50]</td>
<td>[52.00-64.50]</td>
<td>[54.75-71.00]</td>
<td></td>
</tr>
<tr>
<td>Gender (male)</td>
<td>52/72 (73.2%)</td>
<td>12/15 (80.0%)</td>
<td>40/56 (71.4%)</td>
</tr>
<tr>
<td>BMI (kg/m²) (n=47)</td>
<td>31.00</td>
<td>29.09</td>
<td>32.49</td>
</tr>
<tr>
<td>[26.22-34.83]</td>
<td>[24.24-31.46]</td>
<td>[26.57-35.16]</td>
<td></td>
</tr>
<tr>
<td>ARDS</td>
<td>70/71 (98.6%)</td>
<td>14/15 (93.3%)</td>
<td>56/56 (100.0%)</td>
</tr>
<tr>
<td>SAPS 3 (n=18)</td>
<td>49.00</td>
<td>45.50</td>
<td>51.50</td>
</tr>
<tr>
<td>[45.25-55.00]</td>
<td>[41.75-50.25]</td>
<td>[46.00-55.00]</td>
<td></td>
</tr>
<tr>
<td>APACHE II (n=18)</td>
<td>10.00</td>
<td>7.50</td>
<td>11.00</td>
</tr>
<tr>
<td>[7.25-13.75]</td>
<td>[6.00-11.75]</td>
<td>[9.00-13.75]</td>
<td></td>
</tr>
<tr>
<td>Hospital stay (days)</td>
<td>27.00</td>
<td>19.00</td>
<td>28.00</td>
</tr>
<tr>
<td>[19.00-38.00]</td>
<td>[15.00-23.50]</td>
<td>[20.75-41.50]</td>
<td></td>
</tr>
<tr>
<td>Days from symptom onset to ICU admission</td>
<td>9.00</td>
<td>10.00</td>
<td>8.00</td>
</tr>
<tr>
<td>[6.00-12.00]</td>
<td>[8.00-11.50]</td>
<td>[5.00-12.00]</td>
<td></td>
</tr>
<tr>
<td>ICU days</td>
<td>11.00</td>
<td>5.00</td>
<td>15.00</td>
</tr>
<tr>
<td>[7.50-21.50]</td>
<td>[3.50-7.00]</td>
<td>[9.00-26.25]</td>
<td></td>
</tr>
<tr>
<td>High-flow nasal cannula</td>
<td>52/71 (73.2%)</td>
<td>15/15 (100.0%)</td>
<td>37/56 (66.1%)</td>
</tr>
<tr>
<td>Prone positioning during first 7 days</td>
<td>20/71 (28.2%)</td>
<td>1/15 (6.7%)</td>
<td>19/56 (33.9%)</td>
</tr>
<tr>
<td>Days prone positioning (n=20)</td>
<td>2.00 [1.00-3.00]</td>
<td>3.00</td>
<td>2.00 [1.00-4.00]</td>
</tr>
<tr>
<td>Worst PaO2/FiO2 (n=70)</td>
<td>130.00 [109.38-160.93]</td>
<td>117.67 [85.62-131.96]</td>
<td>136.00 [111.19-167.40]</td>
</tr>
<tr>
<td>Death</td>
<td>6/71 (8.5%)</td>
<td>1/15 (6.7%)</td>
<td>5/56 (8.9%)</td>
</tr>
</tbody>
</table>

The values are expressed as the absolute number (percentage) and median (interquartile range).
Objectives: Here, we aimed to evaluate the proteomic changes in inflammatory pathways following repeated FMT at low doses relative to placebo in PWH on effective ART with evidence of incomplete immune recovery and their relationship with other biomarkers (bacteria and plasma molecules).

Methods: We randomized 30 PWH on ART to either weekly fecal microbiota capsules or placebo for eight weeks. Stool donors were selected based on anti-inflammatory microbiota profiles (high Faecalibacterium and butyrate). We measured the plasma expression of 368 inflammatory proteins at weeks 0, 1, 8, and 24 using the Proximity Extension Assay by Olink. We fitted mixed models to compare the protein trajectories and selected the most significant to explore their correlations with 14 bacterial taxa and 7 biomarkers of inflammation. We performed a functional analysis using Gene Set Enrichment Analysis.

Results: FMT resulted in a significant decrease of 54 proteins related to cytokines and leukocyte activation and increase of 2 proteins with anti-inflammatory activity compared to placebo. CCL22, CD22, FGF5, and JUN showed the most consistent pattern of decline after each treatment. We observed changes in the expression of 368 inflammatory proteins measured by Proximity Extension Assay (Olink Proteomics) between FMT and placebo. B. Correlations between differentially expressed proteins and the abundance of 14 relevant bacterial taxa. C. Correlations between differentially expressed proteins and plasma biomarkers of inflammation (4 inflammation proteins and 3 bacterial translocation molecules).
INTRODUCTION: Pregnant women are at increased risk of COVID-19-related intensive care admission, mortality, preterm delivery, pregnancy loss, and stillbirth. Although COVID-19 is usually mild in infants, severe illness and hospitalization can happen in this population. Therefore, protecting the mother-infant dyad against COVID-19 is crucial. Current data show that COVID-19 vaccination of pregnant women can reduce the risk of severe illness in both mothers and their infants. However, additional studies are needed to confirm the magnitude, duration, and protective capacity of the vaccine-induced humoral immune response.

OBJECTIVES: We aimed to assess IgG antibodies against the SARS-CoV-2 spike protein in vaccinated mothers and their infants at delivery and 2-3 months later.

METHODS: We conducted a prospective study on mothers who received at least one dose of the monovalent COVID-19 vaccine during pregnancy and on their infants. The baseline was at delivery (n = 93), and the end of follow-up was 2 to 3 months post-partum (n = 53).

Serum anti-SARS-CoV-2 S IgG titers and ACE2 binding inhibition levels were quantified by immunoassays.

CHARACTERISTICS OF MOTHERS AND INFANTS

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) Mothers</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>93</td>
</tr>
<tr>
<td>Age (years)</td>
<td>34.8 (32.2; 39.1)</td>
</tr>
<tr>
<td>Country of birth</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>74 (79.6%)</td>
</tr>
<tr>
<td>Latin American Countries</td>
<td>15 (16.1%)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (4.3%)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>5 (5.4%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>8 (8.6%)</td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>6 (6.5%)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (3.2%)</td>
</tr>
<tr>
<td>SARS-CoV-2 Infection (+)</td>
<td></td>
</tr>
<tr>
<td>Pre-perinatal (pre-pregnancy and pregnancy)</td>
<td>11 (11.8%)</td>
</tr>
<tr>
<td>Postnatal</td>
<td>21 (39.6%)</td>
</tr>
<tr>
<td>SARS-CoV-2 Vaccine</td>
<td></td>
</tr>
<tr>
<td>First dose</td>
<td></td>
</tr>
<tr>
<td>Pfizer-BionTech (BNT162b2)</td>
<td>66 (71.0%)</td>
</tr>
<tr>
<td>Moderna (mRNA-1273)</td>
<td>26 (27.9%)</td>
</tr>
<tr>
<td>Oxford-AstraZeneca (ChAdOx1-S)</td>
<td>1 (1.1%)</td>
</tr>
<tr>
<td>Second dose (n=79)</td>
<td></td>
</tr>
<tr>
<td>Pfizer-BionTech (BNT162b2)</td>
<td>57 (72.2%)</td>
</tr>
<tr>
<td>Moderna (mRNA-1273)</td>
<td>22 (27.8%)</td>
</tr>
<tr>
<td>Third dose (n=6)</td>
<td></td>
</tr>
<tr>
<td>Pfizer-BionTech (BNT162b2)</td>
<td>4 (66.7%)</td>
</tr>
<tr>
<td>Moderna (mRNA-1273)</td>
<td>2 (33.3%)</td>
</tr>
<tr>
<td>Before pregnancy (n=6)</td>
<td></td>
</tr>
<tr>
<td>First dose</td>
<td>3 (50%)</td>
</tr>
<tr>
<td>Second dose</td>
<td>3 (50%)</td>
</tr>
<tr>
<td>Before childbirth</td>
<td></td>
</tr>
<tr>
<td>First dose</td>
<td>14 (15.1%)</td>
</tr>
<tr>
<td>Second dose</td>
<td>79 (84.9%)</td>
</tr>
<tr>
<td>After childbirth (n=53)</td>
<td></td>
</tr>
<tr>
<td>First dose</td>
<td>7 (13.2%)</td>
</tr>
<tr>
<td>Second dose</td>
<td>40 (75.5%)</td>
</tr>
<tr>
<td>Third dose</td>
<td>6 (11.3%)</td>
</tr>
<tr>
<td>B) Newborns</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>93</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>39.7 (38.3; 40.4)</td>
</tr>
</tbody>
</table>

Mode of delivery

Vaginal                      | 81 (87.1%)  |
Cesarean                     | 12 (12.9%)  |
Sex (male)                   | 53 (57.0%)  |
Breastfeeding                | 88 (94.6%)  |
Condition at birth

APGAR1                      | 9 (9)        |
APGAR5                      | 10 (10)      |
Weight (gr.)                 | 3.300 (3.000; 3.500) |
Height (cm)                  | 50 (49; 51)  |
Head circumference (cm)      | 34 (33; 35)  |
SARS-CoV-2 Infection (+)     |        |
Postnatal                    | 11/53 (20.7%)|

Values are expressed as the median (Q1; Q3) and absolute count (percentage).

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; APGAR, Appearance, Pulse, Grimace, Activity, and Respiration; APGAR1, 1-minute APGAR; APGAR5, 5-minute APGAR.
**Results:** Mothers and children had high anti-SARS-CoV-2 S IgG titers against the B.1 lineage at childbirth. However, while the antibody titers were maintained at 2-3 months post-partum in mothers, they decreased significantly in children (p < 0.001). Positive and significant correlations were found between anti-SARS-CoV-2 S IgG titers and the ACE2 binding inhibition levels in mothers and infants at childbirth and 2-3 months post-partum (r > 0.8, p < 0.001). Anti-S antibodies were also quantified for the Omicron variant at 2-3 months post-partum. In mothers and infants, antibody titers against Omicron were significantly lower than those against B.1 (p < 0.001). Again, a positive correlation was observed for Omicron between IgG titers and ACE2 binding inhibition both in mothers (r = 0.818, p < 0.001) and infants (r = 0.386, p < 0.005). Previous SARS-CoV-2 infection and COVID-19 vaccination near delivery positively impacted anti-SARS-CoV-2 S IgG levels.

(A-B). IgG antibody levels against SARS-CoV-2 S protein (B.1 lineage) at childbirth and 2-3 months post-partum in maternal serum (A) and infant serum (B). (C-D). Inhibition of ACE-S interaction titers (B.1 lineage) at childbirth and 2-3 months post-partum in maternal serum (C) and infant serum (D). Statistics: Differences were calculated by the Wilcoxon test, and only p-values < 0.05 are shown. Medians are represented by a horizontal bar. Abbreviations: AUC, Area under the curve; IgG, anti-SARS-CoV-2 S IgG.

**Conclusions:** COVID-19 mRNA vaccines induce high titers of anti-SARS-CoV-2 S in pregnant women, which can inhibit the binding of ACE2 to protein S and are efficiently transferred to the fetus. However, there was a rapid decrease in antibody levels at 2 to 3 months post-partum, particularly in children.

**Methods:** Biofilms of PA01 and PA14 type strains were generated in Ibitreat chambers (8 wells, OD600nm = 0.1, RPMI-1640), treated with fluticasone, budesonide or v/v DMSO (solvent), observing them under a confocal microscope at 24h (1 µM, therapeutic dose) or 48h (0.1, 1 and 5 µM). The eDNA was stained with Di-YO-1 (0.5-2.5 µM, 15’) prior to confocal observation. Biomass (cells and eDNA) was quantified with COMSTAT. The c-di-GMP (metabolite that promotes and regulates biofilm formation in PA) was quantified using a transcriptional reporter (PA01W_PcdrA:gfP) inoculating it in a plate (96 wells, OD600nm = 0.01, RPMI-1640), and reading the fluorescence every 30’ from 24 to 48h. OMVs were quantified by discarding cells from a culture (18h, 400 ml), ultracentrifuging the supernatant (18h, 400 ml), ultracentrifuging the supernatant (18h, 400 ml), and using NanoSight technology.

**Results:** Although no biomass increase was observed after 24h, this parameter significantly increased after 48h of continuous treatment in a dose-dependent manner, as summarised in the Table, as well as the biomass of eDNA, the release of OMVs and the production of the secondary messenger c-di-GMP.

<table>
<thead>
<tr>
<th></th>
<th>Biomass 24h (µm3/µm2)</th>
<th>Biomass 48h (µm3/µm2)</th>
<th>c-di-GMP OMVs (particles/ml)</th>
<th>DMSO_control</th>
<th>Fluticasone_0.1 µM</th>
<th>Fluticasone_1 µM</th>
<th>Budesonide_0.1 µM</th>
<th>Budesonide_1 µM</th>
<th>Fluticasone_5 µM</th>
<th>Budesonide_0.1 µM</th>
<th>Budesonide_1 µM</th>
<th>Fluticasone_0.1 µM</th>
<th>Fluticasone_1 µM</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA01</td>
<td>7.5</td>
<td>8.4</td>
<td>8.8</td>
<td>78149</td>
<td>3.6</td>
<td>4.5</td>
<td>86321</td>
<td>92159</td>
<td>6.2</td>
<td>96633</td>
<td>8.8</td>
<td>96633</td>
<td>8.8</td>
</tr>
<tr>
<td>PA14</td>
<td>5.4</td>
<td>8.4</td>
<td>9.0</td>
<td>4.5</td>
<td>8.6</td>
<td>8.5</td>
<td>9.2</td>
<td>9.2</td>
<td>8.8</td>
<td>9.2</td>
<td>8.8</td>
<td>9.2</td>
<td>8.8</td>
</tr>
</tbody>
</table>

**Conclusions:** According to our results, corticosteroids promote biofilm formation in PA, increasing its biomass in response to the stress membrane generated by said drugs and with an apparent cumulative effect. Therefore, corticosteroids could participate in the pathophysiology of IBCs due to PA linked to COPD by promoting this characteristic characteristic of strains adapted to chronic lung infection, contributing to the persistence of PA infections in these patients.
92. DRIED BLOOD SPOT USE IN VACCINE RESPONSE MONITORING IN CHILDREN (DRIVE STUDY)

Paula Rodríguez Molino¹,², Ana Rodríguez Galet³,⁴, Jara Hurtado Gallego¹,²,³,⁴, Sonia Alcolea Ruiz¹,²,³, Jorge Atucha¹,²,³, Ana Méndez Echevarría¹,²,³, Iker Falces Romero⁴, Carmen Cámara⁵, Teresa del Rosal¹,³,⁶, Milagros García López-Hortelano¹,²,³, Cristina Calvo¹,²,³, Juan Carlos Galán⁵,⁶, Afrodita Holguín⁵,⁶, Talía Sainz¹,²,³

¹General Pediatrics, Infectious and Tropical Diseases Department, Hospital La Paz, Madrid, Spain. ²Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), Madrid, Spain. ³La Paz Research Institute (IdiPAZ), Madrid, Spain, Madrid, Spain. ⁴Ramón y Cajal Research Institute (IRYCS), Madrid, Spain. ⁵Department of Microbiology, Ramón y Cajal Hospital, Madrid. ⁶Department of Microbiology and Parasitology, La Paz University Hospital, Madrid, Spain. ⁷Department of Immunology, La Paz University Hospital, Madrid, Spain. ⁸Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain. ⁹Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Introduction: Most children with incomplete vaccination reside in countries where vaccination coverage is often unknown. Compared to serum samples, dried blood spots (DBS) are an inexpensive, non-invasive and easy to obtain, conserve and transport alternative, without cold chain requirements. Data on group protection is key for designing strategies to prevent future outbreaks of preventable diseases.

Objectives: To present the first preliminary data of the correlation in paired serum/DBS samples of protective IgG levels against 6 pathogens causing vaccine-preventable diseases in an ongoing prospective project.

Methods: Patients < 18 years old from a tertiary hospital in Madrid (Spain), who were requested serologies for the detection of vaccine antibodies, were included. Dried blood (2-3 cards per patient) was taken simultaneously with samples collected for routine vaccine serology. The presence of G-immunoglobulins (IgG) against 6 vaccine-preventable diseases (diphtheria, tetanus, pertussis, measles, mumps and rubella) was quantified in paired DBS/serum samples using the VirClia-IgG (VIRCELL) technique. In each specific VirClia-IgG test we used 5 µl of serum or 100 µl of a DBS dot eluted in 1 mL of phosphate-buffered saline (PBS), equivalent to 5 µl serum per test. Clinical and epidemiological variables were collected from patients, and the results obtained in DBS were compared with those of conventional serology.

Results: Paired serum/DBS samples were collected from 48 patients < 18 years of age in this preliminary and ongoing study. Different percentage of subjects with protective IgG in serum varied across pathogens: Measles 58%, rubella 85%, mumps 79%, diphtheria 96%, tetanus 68.75% and pertussis 8%. When testing DBS positive results were: measles 56%, rubella 87.5%, mumps 83%, diphtheria 100%, tetanus 66% and pertussis 2%. The correlation between the technique in serum and in DBS for each pathogen is shown in the Figure, ranging from 77% for measles to 98% for mumps. Coincident results were found in all markers in 54.1% of the patients.

Conclusions: Children included in the study had no humoral response against some of the immunopreventable pathogens analyzed, especially against measles, tetanus and pertussis. DBS shows similar results to those obtained in serum with a correlation higher than 80% in all pathogens except for Measles. Our preliminary results, when confirmed with a larger set of paired DBS/serum, will support the DBS utility to monitor vaccination coverage in seroprevalence studies in resource-limited settings in the absence of serum specimens.

Funding: This study is founded by European Society for Pediatric Infectious Diseases (ESPID).

93. DISTINCTIVE ANTIBODY PROFILE IN PATIENTS WITH POST-COVID-19 CONDITION

Gemma Moncunill¹, Ruth Aguilar¹, Hugo Rozas¹, Daniela Modena², Marta Vidal¹, Alfons Jimenez¹, Brian Silva¹, Didac Macià¹, Mar Canyelles¹, Lucía Carrasco¹, Concepción Violán², Diana Puente³, Carlota Dobaño¹, Anna Berenguer¹

¹ISGlobal, Barcelona, Spain. ²IDIAPJGol, Barcelona, Spain.

Introduction: Post-COVID-19 condition (PCC) affects around 10% of people infected with SARS-CoV-2, who continue to present symptoms months after the infection, which range from mild to debilitating. The lack of specificity of the PCC definition and the overlap of symptoms with other diseases leads to a delay in the diagnosis.

Objectives: The objective of this project is to identify biomarkers and mechanisms underlying PCC, assessing reactivation of viral infections, autoimmunity, immune dysregulation and other alterations. Specific objectives for this presentation include: i) the identification of clusters of symptoms; ii) the identification of anti-SARS-CoV-2 antibody patterns associated with clusters and symptoms; iii) and the assessment of herpes viruses reactivation.

Methods: 426 PCC were recruited from November 2021 to May 2022. Blood samples were collected for serological determinations, and demographic and clinical information was collected in self-filled questionnaires. Cluster analysis of symptoms was performed using the Multiple Correspondence Analysis algorithm followed by a K-Means. IgG, IgM and IgA were measured by Luminex against 11 SARS-CoV-2 antigens: Spike (S), RBD, S1, S2, nucleocapsid (N) and RBD from variants of concern: delta and omicron (BA1.1, BA2, BA4/5, BQ1.1 and XBB); and 6 herpes antigens from CMV, EBV, HSV1 and VZV. Antibody levels between groups were compared using Kruskall-Wallis and Wilcoxon tests.

Results: Mean age of the participants was 47.65 years (SD 9), 80% were females and 11.7% had comorbidities. Mean time since onset of
symptoms was 544 days (SD 141.6). Participants had a mean of 9.11
symptoms (SD 4.48) and 85.7% received COVID-19 vaccines. Four clus-
ters were identified: one with high number of symptoms and three
with lower number of symptoms: one with higher prevalence of car-
diovascular symptoms, one with higher prevalence of menstrual
symptoms, and a third with no specific symptoms. There were few
differences in antibody levels between clusters, with higher RBDs IgA
and IgG and S1 IgG in the cardiovascular cluster and a tendency for
lower levels in the cluster with high number of symptoms. Differential
antibody profile was also detected for specific symptoms like fe-
ver, vomiting, dysgeusia/anosmia, sexual desire, and menstruation
alterations. Menstrual alteration was associated with several dif-
fences with higher RBDs, N, CMV, EBV and VZV IgM levels and lower
RBDs and S IgG and IgA levels.

Conclusions: Preliminary analyses of antibody responses show spe-
cific profiles associated to symptoms and clusters of symptoms, espe-
cially cardiovascular and menstrual, reflecting altered antibody re-
sponses to SARS-CoV-2 and herpes viruses in these phenotypes.
Funding: Fundació Privada Daniel Bravo Andreu, CIBERINFEC.

96. IN VITRO RESISTANCE DEVELOPMENT TO IMIPENEM/
RELEBAC TAM IN KPC-PRODUCING KLEBSIELLA PNEUMONIAE
INVOLVES MULTIPLE MUTATIONS INCLUDING OMPK36
DISRUPTION AND KPC MODIFICATION

Jorge Arca-Suárez1-4, Eva Gato1, Isaac Alonso-García1,
Juan Carlos Vázquez-Ucha1,2, Marta Martínez-Guitián1,2,
Tania Blanco-Martín2, Rosa Pedraza-Merino4, Michelle Outeda1,
Romina Maceiras1, Cristina Lasarte-monterrubio1, Concepción González-Bello1, Luis Martínez-Martínez1,2,3,
Alejandro Beceiro1,2, Germán Bou1,2,3
1Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CB21/13/00055, Instituto de Salud Carlos III, Madrid, Spain.
3Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CB21/13/00055-Instituto de Salud Carlos III, Madrid, Spain.
4Hospital Universitario Reina Sofía, Córdoba, Spain.
5Universidad de Santiago de Compostela, A Coruña, Spain.
6Hospital Reina Sofía, Córdoba, Spain.
7Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CB21/13/00049, Instituto de Salud Carlos III, Madrid, Spain.
8Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CB21/13/00055-Instituto de Salud Carlos III, Madrid, Spain.

Introduction: Imipenem/relebactam (IMR) and ceftazidime/avibact-
am (CZA) are two recently developed beta-lactam/beta-lactamase
inhibitor with high activity against KPC-producing Klebsiella pneu-
niae.

Objectives: To predict potential strategies aimed at combating KPC-
producing K. pneumoniae infections, we comparatively analysed IMR and CZA resistance development dynamics and resistance mech-
nisms in high-risk clones of KPC-2 and KPC-3-producing K. pneu-
niae.

Methods: Two high-risk clones of KPC-2 (AI3042, ST11; AI2713,
ST273) and KPC-3 (AI2811, ST512; AI2644, ST307)-producing K. pneu-
niae clinical strains were evaluated. Resistance dynamics were
determined in triplicate experiments through incubating each strain
during 7 days in 10-mL Mueller-Hinton (MH) tubes containing 2x in-
cremental concentrations of each antibiotic combination up to their
64x baseline MICs. Selected mutants were characterized through WGS. MICs were determined by reference broth microdilution. Impact on
β-lactam resistance of KPC-vatants selected under IMR exposure were
evaluated through cloning in an Escherichia coli HB4 background
(OmpC and OmpF-deficient). KPC-2 and the IMR-selected KPC-2
N132S variant were purified and inhibition constants with relebactam
were determined. The role of the N132S substitution on relebactam
resistance was explored via molecular modeling. Growth rates in MH
of parental and antibiotic-selected strains were assessed by continu-
ously monitoring the OD600 until late-log phase using an Epoch 2
microplate spectrophotometer.

Results: Results: In all cases clinical strains developed resistance to
both combinations.Mutants selected with CZA showed changes in KPC
associated with high-level CZA resistance (16 - > 512 mg/L) but carbap-
emem susceptibility. Mutants selected with IMR developed IMR resis-
tance (range from 4-128 mg/L) but collateral changes in the MIC of the
rest of β-lactams which differed throughout the different mutants.
IMR-selected mutants tended to accumulate mutations in genes cond-
ing for OmpK36, PBP2, KPC (S106L and N132S in KPC-2 and L167R
in KPC-3) and other proteins associated with cell-wall and membrane
functions were found in several mutants. E. coli HB4 KPC transformants
demonstrated that the IMR-selected variants KPC-2 N132S and KPC-3
L167R confer IMR resistance. Inhibition kinetics and structural analysis
demonstrate that the N132S mutation dramatically reduced the poten-
cy of relebactam inhibition (in terms of IC50, K2/K, tn) through rear-
rangement of the KPC-2 active site. Compared to CZA, a higher propor-
tion of mutants selected with IMR exhibited impaired growth.

Conclusions: Development of resistance to IMR in KPC-producing K.
pneumoniae is associated with OmpK36 inactivation, KPC modifica-
tion, strain-specific mutations and high fitness costs. Substitutions
L167R and N132S confer resistance to imipenem/relebactam through
modification of the KPC active site which results in a major increase on
resistance to the inhibitor.

Funding: This work was supported by MSD through the Investigator
Initiated Studies Program, which provided financial support (to G.B.)
and relebactam. This work was also supported by the Fondo de Inves-
tigación Sanitaria (grant numbers PI17/01482 and PI20/02212 for A.B.,
and PI18/00501 and PI21/00704 for G.B.). Integrated in the Plan Nacio-
nal de I+D and funded by the Instituto de Salud Carlos III, ISCIII.
CIBER-INFEC (CIBER de Enfermedades Infecciosas). The research was also
funded by the Spanish Network of Research in Infectious Diseases (RI-
PI), N° RD16/016/0006 and N° RD16/016/0006, integrated in the Na-
tional Plan for Scientific Research, Development and Technological
Innovation 2013–2016 and funded by the ISCIII–General Subdirection of
Assessment and Promotion of the Research–European Regional Devel-
opment Fund (FEDER) “A way of making Europe.” The study was also
funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Econo-
mia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22,
G.B.). PCS was financially supported by IN606A-2021/021. I.A.-G was
financially supported by the Rio Hortega program (ISCIII, CM21/00076).
J.C.V.-L. was financially supported by the ISCIII project FI18/00315.
C.L.-M. was financially supported by IN606A-2019/029, J.A.-S. was fi-
ancially supported by the Juan Rodés program (ISCIII,R21/00026).
Financial support from the Spanish Agency of Research (PID2019-
105512RB-100/AEI/10.13039/501100011033, CG-B), the Xunta de Galicia
[ED431C 2021/29 and the Centro singular de investigación de Galicia
accreditation 2019-2022 [ED431G 2019/03], CG-B], and the European
Regional Development Fund (ERDF) is gratefully acknowledged. AC ac-
knowledges to Banco Santander for his fellowship. We are also grateful
to the Centro de Supercomputación de Galicia (CESGA) for use of the
Finis Terrae computer.

98. DEVELOPMENT AND INTERNAL VALIDATION OF A PREDICTIVE
MODEL SCORE FOR MORTALITY IN PATIENTS WITH
BLOODSTREAM INFECTIONS. DATA FROM THE PROBAC
PROSPECTIVE MULTICENTRE COHORT

Sandra de la Rosa Riestra1, Pedro María Martínez Pérez Crespo2,
Fatima Galán3, Inmaculada López Hernández1, Jesús Rodríguez Baño1, Luis Eduardo López Cortes1
1Virgen Macarena University Hospital, Seville, Spain. 2Valme University
Hospital, Seville, Spain. 3Puerta del Mar University Hospital, Cadiz, Spain.
Introduction: Bloodstream infections are an important mortality cause. Although some mortality predictive scores have been validated, most of them were developed years ago; recent changes in epidemiology and management would require updated prediction systems.

Objectives: Our purpose was to develop a mortality predictive model in bloodstream infections.

Methods: A prospective cohort including consecutive adults with bacteraemia collected between October 2016 and March 2017 in 26 hospitals in Spain was analysed. We excluded patients who died during the first 24 hours and we created a derivation cohort (DC) and a validation cohort (VC) with randomly chosen 2/3 and 1/3 of patients respectively. The primary outcome was all-cause 30-day mortality. A logistic regression model was developed in DC for mortality predictors, with punctuation assignments to the selected variables; the model was applied to VC. Then we excluded patients who died during the first 48 hours and applied the model in the resulting group to assess if the discriminative power was good even in this group of patients. We repeated the model combining our variables with some currently utilised scores: Charlson-age-adjusted ≥ 2, Pitt ≥ 2 and SOFA ≥ 2 as dichotomised variables and compared the resulting models with our model through discriminative value.

Results: Overall, 6,111 patients were included. Mortality was 11.8%, 95%CI (10.7-12.9) and 12.3% (95%CI 10.6-13.9) (p: 0.53) in DC and VC, respectively. Epidemiological features, predisposing factors, appropriateness empirical and targeted therapy, microorganisms, severity and source of infection did not show statistically significant differences in DC and VC. The variables selected in multivariate model for DC with the points assigned are shown in the Table. The AUROC of the model was 0.82 95%CI (0.80-0.84). After applying the scoring system to the VC, we obtained a similar AUROC. Sensitivity, specificity, positive and negative likehood ratio and negative predictive value, positive and negative likehood ratio and VC, we obtained a similar AUROC. Sensitivity, specificity, positive and negative likehood ratio and negative predictive value, positive and negative likehood ratio and negative likehood ratio were worse than the one obtained in our original model.

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR adjusted 95%CI p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age:</td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>Reference</td>
</tr>
<tr>
<td>&gt; 60</td>
<td>1.45 1.09-1.94 &lt; 0.001</td>
</tr>
<tr>
<td>McCabe fatal condition.</td>
<td>2.30 1.70-3.11 &lt; 0.001</td>
</tr>
<tr>
<td>Cancer</td>
<td>4.34 3.40-5.54 &lt; 0.001</td>
</tr>
<tr>
<td>Liver disease.</td>
<td>4.34 3.40-5.54 &lt; 0.001</td>
</tr>
<tr>
<td>High risk aetiology (S. aureus, P. aeruginosa, A. baumannii, E. faecium, E. faecalis, L. monocytogenes y S. marcescens)</td>
<td>1.41 1.29-2.57 0.006</td>
</tr>
<tr>
<td>Consumption broad spectrum antibiotics during the previous month (third or fourth generation cephalosporins, piperacillin-tazobactam, carbapenems, aminoglycosides or glucocorticoids)</td>
<td>1.82 1.42-2.22 &lt; 0.001</td>
</tr>
<tr>
<td>High risk sources of infection (unknown, central nervous system, respiratory, abdominal except biliary tract)</td>
<td>2.05 1.58-2.66 &lt; 0.001</td>
</tr>
<tr>
<td>Polymicrobial bloodstreaminfection</td>
<td>1.49 1.17-1.90 &lt; 0.001</td>
</tr>
<tr>
<td>Stupor or coma</td>
<td>1.72 1.36-2.18 &lt; 0.001</td>
</tr>
<tr>
<td>MBP &gt; 70 mmHg or requirement of vasoactive amines</td>
<td>1.70 1.15-2.51 0.007</td>
</tr>
<tr>
<td>PaO2/FiO2 ≤ 300 or equivalent</td>
<td>1.62 1.26-2.08 &lt; 0.001</td>
</tr>
</tbody>
</table>

Conclusions: We developed and internally validated a prognostic scoring system based in a large, multicentre cohort, which showed a good discrimination power.

Funding: ISCIII(PI16/01432).

100. ASSESSING THE IMPACT OF THE MOST RELEVANT CHROMOSOMALLY-ENCODED AND HORIZONTALLY-ACQUIRED PSEUDOMONAS AERUGINOSA RESISTANCE MECHANISMS ON RESISTANCE TO CEFIDEROCOL, IMIPENEM/RELEBATAM, CEFEPIME/TANIBORBACTAM, CEFEPIME/ZIDEBACTAM AND AZTREONAM/AVIBACTAM

Juan Carlos Vázquez-Ucha1, Isaac Alonso-García2, Pablo Arturo Fraile-Ribot1, Cristina Lasarte-Montserraturbio2, Paula Guijarro-Sánchez2, Soraya Rumbo-Feal3, Michelle Outeda4, Romina Maceiras4, Marta Martínez-Guitián2, Alejandro Becerro4, Carlos Juan1, German Bou1, Antonio Oliver1, Jorge Arca-Suárez1

1Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), Madrid, Spain. 3Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Palma, Spain.

Introduction: Cefiderocol, imipenem/relebactam, cefepime/tanibor- bactam, cefepime/zidabeactam and aztreonam/avibactam are antimicrobial agents that demonstrate high activity against MDR Pseudomonas aeruginosa strains. However, the precise mechanisms that may compromise their effectiveness in this pathogen remain poorly un- derstood.

Objectives: We sought to precisely determine the impact of the most relevant chromosomal and horizontally-acquired P. aeruginosa resistance mechanisms on the effectiveness of these new agents.

Methods: We constructed a collection of 42 PA01 derivatives. Twenty-three of them were obtained via cloning assays using the pUCP-24 plasmid and included recombinant isolates expressing the most widespread class A (GES, PER, VEB and KPC variants), B (VIM, IMP and NDM variants), C (FOX-4) and D (OXA-14, OXA-15 and OXA-48) hori- zontally-acquired β-lactamas in P. aeruginosa. The other 19 isolates were obtained via the crelox system for gene deletion and included a collection of PA01 knockout mutants expressing the most frequent chromosomally encoded resistance mechanisms found in this pathogen: overexpression of blaPDC, efflux pumps (mexAB-oprM, mexXY, and mexCD-oprJ) and oprD deficiency, including isolates simultaneously expressing multiple of these mechanisms. MICs were deter- mined by reference broth microdilution.

Results: Cefiderocol demonstrated excellent in vitro activity (MICs ≤ 0.5–2 mg/L) for most of isolates producing horizontally-acquired en- zymes with the exception of isolates producing PER-1 (MIC = 32 mg/L) or NDM variants (MIC = 8 mg/L). Imipenem/relebactam was active against isolates producing class A and C β-lactamas, although it was found inactive against MBL and OXA-48-producing isolates and against 2 producers of imipenem/relebactam-selected KPC deriva- tives (KPC-2 N132S and KPC-3 L167R). The activity of cefepime/tani- borbactam was only limited against isolates producing IMP and NDM- type enzymes, whereas cefepime/zidabeactam and aztreonam/avibactam were active against all transformants (MICs 2–8 mg/L and 4–16 mg/L respectively). Besides, cefiderocol (MICs ≤ 0.12-0.25 mg/L) and imipenem/relebactam (MICs 0.25–1 mg/L) retained activity against isolates showing chromosomal resistance, whereas efflux pumps significantly raised the MICs of aztreonam/avibactam (Mex- AB-OpnR, MIC = 8 mg/L), cefepime/taniborbactam (MexAB-OpnR, MexXY and MexCD-OprJ, MIC = 8 mg/L), cefepime/zidabeactam and zidabeactam alone (MexAB-OpnR, MICs of 8 and 16–32 mg/L, re- spectively).

Conclusions: These agents show complementary in vitro activity against P. aeruginosa resistance mechanisms. Cefiderocol and imipen- nem/relebactam show higher stability against mutational resistance than aztreonam/avibactam and cefepime-based combinations, which are significantly affected by efflux.
102. ROLE OF INTESTINAL MICROBIOTA COMPOSITION IN HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Claudia González-Rico1,2, Sara Fernández-Luis3, Jorge Rodríguez-Grande4, Marta Hernández Pérez5, Francisco Arnaiz de Las Revillas Almajano1,2, Lucrecia Yañez San Segundo1,6, Arancha Bermúdez Rodríguez3,6, Alain Ocampo-Sosa4,2, Jorge Calvo Montes4,2, Marta Fernández-Martínez7,2, M. Carmen Fariñas Álvarez1,6,2

1Infectious Diseases Service, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 3Haematology Service, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain. 4Microbiology Service, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain. 5Agricultural Technology Institute of Castilla and León (ITACYL), Valladolid, Spain. 6University of Cantabria, Santander, Spain. 7HSC Processing and Cell Therapy Unit, Blood and Tissue Bank of Cantabria, Marqués de Valdecilla Foundation, Hospital de la Santa Cruz de Liencres, Liencres, Spain.

Introduction: The microbiota appears to play an important role in the success of HSCT and the development of graft-versus-host-disease (GVHD). The dysbiosis that occurs during HSCT may lead to increased colonization by pathogenic microorganisms, such as multidrug-resistant Enterobacteriaceae (MDRE), and thus an increased risk of infection by these microorganisms.

Objectives: The aim of this study was to analyse the composition of the intestinal microbiome during HSCT, its relationship with the clinical outcome of patients and MDRE colonization.

Methods: A prospective cohort study was conducted between June 2017 and June 2021 in Marqués de Valdecilla University Hospital. Stool samples were collected before HSCT and on days 14, 30, 60 and 100 following transplantation. The V3-V4 region of the 16S rDNA was sequenced on Illumina MiSeq and the sequences were processed using the QIIME2 pipeline. All samples were down-sampled to 10k reads. Only taxa with a frequency of at least 0.2% in the analysed sample were selected. Patient outcomes were followed up to one year after HSCT.

Results: This is a preliminary analysis of 92 samples from 19 patients. The clinical characteristics of the patients are listed in the Table. Taxonomic profile of the intestinal microbiota by time and colonization status are represented in the Figure. The most abundant phylum are Firmicutes, followed by Actinobacteriota and Verrucomicrobiota. Several diversity metrics were performed to determine alpha and beta diversity. Non-metric multidimensional scaling (NMDS) analyses of Bray-Curtis, Jaccard and Shannon indices do not allow us to observe distinct groups when gathering the population according to some characteristics. Probably due to the small number of patients analysed.

Conclusions: No significant differences were observed in the composition of the microbiota regarding to different characteristics of patients. Further analysis are needed to understand the relevance of the microbiome in these patients.

Funding: Supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases-cofi.

Characteristics of the study population

<table>
<thead>
<tr>
<th>Patients (N = 19)</th>
<th>Male/Female, n (%)</th>
<th>HCT-CI score, median (IQR)</th>
<th>Risk factors, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Conditioning regimen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Myeloablative</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-myeloablative</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GVHD prophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CsA + MMF</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CsA + MTX</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tacrolimus + MMF</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cyclophosphamide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cyclophosphamide + Tacrolimus + MMF</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Infections (3 months prior)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Antibiotic treatment (3 months prior)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Colonization by MDRE, n (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Before HSCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>After HSCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Post-transplant factors, n (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Episode of MDRE Infection</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute GVHD episode</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chronic GVHD episode</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Underlying disease remission</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Underlying disease recurrence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Death (1 year after HSCT), n (%)</td>
</tr>
</tbody>
</table>

HCT-CI: Hematopoietic cell transplantation-specific comorbidity index; IQR: Interquartile Range; GVHD: Graft-Versus-Host Disease; CsA: Cyclosporine; MMF: Mycophenolate mofetil; MTX: Methotrexate; MDRE: multidrug-resistant Enterobacteriaceae; HSCT: haematopoietic stem cell transplant.
**104. EVALUATION OF NUCLEAR MAGNETIC RESONANCE-BASED URINE METABOLIC PROFILING TO MONITOR TREATMENT RESPONSE IN CHILDREN WITH TUBERCULOSIS**

Andrea Lopez-Suárez,4,5 Paula Rodríguez-Molino4,5, Yaiza Marin Olivería, María del Pilar Alonso-Moreno1, Patricia Comella del Barrio1,2, Antoni Noguera-Julian3, Daniel Blazquez-Gamero3, Ana Belen Jiménez10, Jara Hurtado Gallego2,4,5, Sonia Alcolea Ruiz2,4,5,1, Jorge Atucha2,4,5, Talia Sainz Costa2,4,5, Josef Luis Izquierdo-García2,6,12, Beogoña Santiago-Garcia1

1Pediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infectiosas (CIBERINFEC), Madrid, Spain. 3Gregorio Marañón Research Health Institute (IISGM), Madrid, Spain. 4General Pediatrics, Infectious and Tropical Diseases Department, Hospital La Paz, Madrid, Spain. 5La Paz Research Institute (IdiPAZ), Madrid, Spain. 6NMR and Imaging in Biomedicine Group, Instituto Pluridisciplinar, Universidad Complutense de Madrid, Madrid, Spain. 7Pediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón, Madrid, Spain. 8Pediatric Infectious Diseases Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues de Llobregat, Barcelona, Spain. 9Pediatric Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Universidad Complutense, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain. 10Pediatric Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. 11La Paz Research Institute (IdiPAZ), Madrid, Spain. 12Department of Chemistry in Pharmaceutical Sciences, Pharmacy School, Universidad Complutense de Madrid, Madrid, Spain.

**Introduction:** In tuberculosis (TB) management, monitoring patients’ progress during treatment is crucial to assess clinical response, and may be useful in deciding on the implementation of new short regimens. Recent research has shown the potential of urine metabolomics as a diagnostic and prognostic tool for TB. Nuclear Magnetic Resonance (NMR)-based metabolomics provides a unique fingerprint of the disease’s metabolic status, making it a powerful tool for evaluating TB.

**Objectives:** This proof-of-concept study aims to follow the urinary metabolic profile of pediatric TB patients during anti-TB treatment. Urine is a promising sample for evaluating pediatric TB, as it is an easy and non-invasive sample to collect. The objectives of the study were to determine the urine metabolic fingerprint at different timepoints and analyze longitudinal changes in metabolomic profiles during treatment.

**Methods:** The study included 145 patients under 18 years of age from 10 hospitals belonging to the Spanish Pediatric TB Network (Table). Urine samples were collected at diagnosis, at 2 months, and at the end of treatment (4-6 months). The samples were analyzed using a 500 MHz Bruker NMR spectrometer at the Complutense University of Madrid (CIBERES). NMR spectra were processed using MNova software (Mestrelab Research, Santiago de Compostela). Multivariate Statistical Analysis were performed using Metaboanalyst web application. PLS-DA models were applied to investigate significant differences in the metabolic profile between samples collected at different time points. Variable Importance in Projection (VIP) was calculated to identify the metabolic signals that discriminate between groups.

**Results:** Preliminary results from 35 children with active TB show a metabolic reprogramming during anti-TB treatment. PLS-DA provided good discrimination between samples collected at diagnosis and at 2 months of the treatment, with an accuracy in the cross validation of 75% (Q2 = 0.18). A second PLS-DA model discriminated between samples collected at 2 months and at the end of treatment, with an accuracy in the cross validation of 79% (Q2 = 0.30). More than 80 NMR signals were identified as important in the classification.

**Conclusions:** We have identified an NMR-based metabolic profile in urine that may be capable to monitor disease progression during treatment.

<table>
<thead>
<tr>
<th>Variables</th>
<th>All (n = 145)</th>
<th>Active TB (n = 95)</th>
<th>Latent TB (n = 24)</th>
<th>TB contacts (Controls) (n = 26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Girls</td>
<td>59 (40.7%)</td>
<td>40 (42.1%)</td>
<td>6 (25.0%)</td>
<td>13 (50.0%)</td>
</tr>
<tr>
<td>Boys</td>
<td>86 (59.3%)</td>
<td>55 (57.9%)</td>
<td>18 (75.0%)</td>
<td>13 (50.0%)</td>
</tr>
<tr>
<td>Age &lt; 1 year</td>
<td>12 (8.3%)</td>
<td>9 (9.5%)</td>
<td>0 (0.0%)</td>
<td>3 (11.5%)</td>
</tr>
<tr>
<td>1-5 years</td>
<td>48 (33.1%)</td>
<td>36 (37.9%)</td>
<td>4 (16.7%)</td>
<td>8 (30.8%)</td>
</tr>
<tr>
<td>5-12 years</td>
<td>46 (31.7%)</td>
<td>22 (23.1%)</td>
<td>16 (66.6%)</td>
<td>8 (30.8%)</td>
</tr>
<tr>
<td>&gt; 12 years</td>
<td>39 (26.9%)</td>
<td>28 (29.5%)</td>
<td>4 (16.7%)</td>
<td>7 (26.9%)</td>
</tr>
<tr>
<td>BCG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>23 (15.9%)</td>
<td>15 (15.8%)</td>
<td>5 (20.8%)</td>
<td>3 (11.6%)</td>
</tr>
<tr>
<td>No</td>
<td>111 (76.5%)</td>
<td>74 (77.9%)</td>
<td>16 (66.7%)</td>
<td>21 (80.7%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>11 (7.6%)</td>
<td>6 (6.3%)</td>
<td>3 (12.5%)</td>
<td>2 (7.7%)</td>
</tr>
<tr>
<td>TST</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>94 (64.8%)</td>
<td>78 (82.1%)</td>
<td>15 (62.5%)</td>
<td>1 (3.9%)*</td>
</tr>
<tr>
<td>Negative</td>
<td>22 (15.2%)</td>
<td>8 (8.4%)</td>
<td>1 (4.2%)</td>
<td>13 (50.0%)</td>
</tr>
<tr>
<td>Not performed</td>
<td>29 (20.0%)</td>
<td>9 (9.5%)</td>
<td>8 (33.3%)</td>
<td>12 (46.1%)</td>
</tr>
<tr>
<td>QFT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>96 (66.2%)</td>
<td>74 (77.9%)</td>
<td>20 (83.1%)</td>
<td>1 (3.9%)*</td>
</tr>
<tr>
<td>Negative</td>
<td>34 (23.5%)</td>
<td>10 (10.5%)</td>
<td>1 (4.2%)</td>
<td>24 (92.3%)</td>
</tr>
<tr>
<td>Indeterminate</td>
<td>6 (4.1%)</td>
<td>3 (3.2%)</td>
<td>2 (8.3%)</td>
<td>1 (3.8%)</td>
</tr>
<tr>
<td>Not performed/UNK</td>
<td>9 (6.2%)</td>
<td>8 (8.4%)</td>
<td>1 (4.2%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Treatment length</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 months</td>
<td>12 (8.3%)</td>
<td>3 (3.2%)</td>
<td>6 (25.0%)</td>
<td>3 (11.5%)</td>
</tr>
<tr>
<td>3-6 months</td>
<td>74 (51%)</td>
<td>61 (64.2%)</td>
<td>13 (54.2%)</td>
<td>1 (3.9%)</td>
</tr>
<tr>
<td>&gt; 6 months</td>
<td>20 (13.8%)</td>
<td>16 (16.8%)</td>
<td>4 (16.7%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Observation</td>
<td>22 (15.2%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>22 (84.6%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>17 (11.7%)</td>
<td>15 (15.8%)</td>
<td>1 (4.1%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Drug susceptibility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susceptible</td>
<td>-</td>
<td>35 (36.8%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Monoresistant</td>
<td>-</td>
<td>3 (3.2%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Poliresistant</td>
<td>-</td>
<td>1 (1.1%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Unknown</td>
<td>56 (58.9%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

The cohort included 95 children with active TB, 24 cases of latent TB infection (LTI), and 26 TB contacts as controls. The mean age of the cohort was 7.7 years old.*Positive TST result in a control patient with treated tuberculosis infection. **Possible false positive.

**Score plot of PLS-DA performed on the 1H NMR spectra of urine samples from pediatric tuberculosis patients collected A) at diagnosis (green) and at 2 months (red); B) at 2 months (red) and at the end of treatment (green). Samples from three groups are clearly separated.**
treatment and evaluate the outcome of treatment success. This urine metabolomic approach could be applied to monitor individualized treatment regimens of patients with longer treatment time and poor treatment outcomes as patients treated for drug-resistant TB. Funding: This research was supported by grants: (i) PID2019-10656RJ-I00 from the Spanish Ministry of Science and Innovation and grant P20/01607 from ISCIII AES 2020.

105. HYBRID IMMUNITY AGAINST VARIANTS OF CONCERN IN PEOPLE VACCINATED WITH TWO DOSES OF SPIKEVAX: EFFECT OF TIMING OF VACCINATION

Javier García-Pérez1, Mercedes Bermejo1, Almudena Ramírez García1, Humberto Erick de la Torre Tarazona1, Almudena Cacacjero1, María Castillo de la Osa1, Paloma Jiménez1, Marta Aparicio Gómez1, Esther Calonge1, Aránzazu Sancho-López2, Concepción Payarés-Herrera2, Rocío Layunta-Acero2, Laura Vicente-Izquierdo2, Cristina Avendaño-Solá2, José Alcamí1, Mayte Pérez-Olmeda1, Francisco Díez-Fuertes1

1Instituto de Salud Carlos III, Majadahonda, Spain. 2Hospital Universitario Puerta de Hierro, Majadahonda, Spain.

Introduction: The effectiveness of hybrid immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) re-infection is a matter of debate, especially after the appearance of the highly diversified sublineages of omicron variant associated with a high transmissibility and immune evasion.

Objectives: This study aims to evaluate the humoral immune response elicited against SARS-CoV-2 variants of concern (VOCs) Alpha, Beta, Delta, and Omicron in recovered and naïve people vaccinated with two doses of SpikeVax (Moderna). To evaluate the effect of extending the vaccination schedule we compared the impact of immunization 1–3 months (Rec2m) versus 4–12 months (Rec9m) after the natural infection in recovered patients.

Methods: Sera from 66 health care workers were collected at days 0, 28 and 42 after the first dose of SpikeVax. A total of 31 out of the 66 participants had a documented prior history of SARS-CoV-2 infection, including 17 (53.1%) Rec2m within three months before vaccination and 14 (43.7%) Rec9m with a documented infection from 4 to 12-months before vaccination. Antibody-mediated immune responses were assessed by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay.

Results: Levels of immunoglobulins (Ig) to SARS-CoV-2 were lower in naïve participants at post-boost as compared with convalescents after a single dose of SpikeVax (p < 0.05). In recovered patients, after two vaccine doses total Ig to RBD were higher in Rec9m (21,618 BAU/ml; 95%CI: 18,092-25,831) as compared to Rec2m (10,219 BAU/ml; 95%CI: 7,572-13,792 BAU/ml) (p < 0.001). These differences were also observed for anti-trimeric spike IgG levels and anti-spike IgA. The SARS-CoV-2 neutralization titer 50 (NT50) observed in recovered participants after a single dose was consistently higher than in naïve.

A, B, C, D, E, F: NT50 levels in pseudovirus neutralization assay in naïve, Rec2m and Rec9m vaccine recipients against SARS-CoV-2 variants D614G (A), Alpha (B), Beta (C), Delta (D), Mu (E), and Omicron (F). NT50 was summarized as geometric mean and 95% confidence interval.
participants after two doses of SpikeVax against the ancestral variant G614 (1.7-fold), and VOCs Alpha (1.9-fold), Beta (2.7-fold), Delta (1.1-fold), and Omicron (2.7-fold). Fourteen days after the second dose of SpikeVax, the neutralizing potency observed in Rec9m was consistently higher than in Rec2m against VOCs Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2–2.8-fold increases.

Conclusions: Increasing more than 3 months the interval between SARS-CoV-2 infection and the immunization with mRNA-based vaccines generates a more efficient humoral immune response against VOCs. This improvement can be related with the time requested to mount a strong recall memory B cell response. Ongoing studies include the neutralization response against the new omicron variants circulating in Spain and the analysis of B and T cell responses in the participants.

Funding: Instituto de Salud Carlos III, CIBERINFEC.

106. RATES OF FAECAL/OROPHARYNGEAL COLONIZATION AND INFECTION BY MULTIRESISTANT GRAM-NEGATIVE BACTERIA AMONG PATIENTS ADMITTED TO SEVEN ICUS IN SPAIN: MURAN-UCI PROJECT

Javier Cañada-García1, Enrique Alemparte-Pardavila2, Ester del Barrio Tofioño1, Mercedes Delgado1, Desiree Gijón Cordero3, Claudia González-Rico4, Cristina Riazzo5, Estrella Rojo-Moliner6, Francisco J Arroyo Muñoz7, Jorge Arca-Suárez8, Sergio García-Fernández9, Alba Mir-Cros10, Carla López-Causapé11, Jorge Rodríguez-Gómez12, Patricia Ruiz-Garbajosa13, Eva Ramírez de Arellano1

1Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid; CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. 2Complejo Hospitalario Universitario A Coruña, Servicio de Medicina Intensiva; A Coruña, Spain. 3Hospital Universitario Vall d’Hebron, Servicio de Microbiología; IBER Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain. 4Hospital Universitario San Espasmes, Palma de Mallorca, Baleares, Servicio de Microbiología; CIBER Enfermedades Infecciosas (CIBERINFEC), Palma de Mallorca, Spain. 5Hospital Universitario Virgen Macarena, Sevilla, Servicio de Microbiología; CIBER Enfermedades Infecciosas (CIBERINFEC), Sevilla, Spain. 6Hospital Universitario Ramón y Cajal, Madrid, Servicio de Microbiología; CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.

Introduction: Although there are multiple bacteria that cause infections and outbreaks in ICUs, multidrug-resistant Gram-negative bacteria are the main challenge in ICUs around the world, mainly the carbapenemase-producing Enterobacteriales (CPE), ESBL-producing Enterobacteriales, and carbapenem-resistant (CR) Pseudomonas aeruginosa and Acinetobacter spp. The objective of this study is to know the impact of colonization/infection by these microorganisms in Spanish ICUs.

Objectives: To study the prevalence of colonization/infection on admission to ICUs of CPE, ESBL-producing Enterobacteriales, and carbapenem-resistant (CR) P. aeruginosa and Acinetobacter spp., as well as their incidence acquired during the stay in ICUs.

Methods: All patients admitted to ICUs of seven Spanish hospitals during February 15th to March 30th, 2023, were included. Carrier status was studied by surveillance cultures of rectal and oropharyngeal exudates on admission, one week, and two weeks. The prevalence of colonization at admission and the incidence of colonization acquired during the stay in ICUs by CPE, ESBL-producing Klebsiella pneumoniae, and CR P. aeruginosa and Acinetobacter spp. were calculated. Information on infections caused by these bacteria was also recorded.

Results: 772 patients were included. The pooled prevalence of colonization by the bacteria under study upon admission was 3.10% (24/772) [interhospital range: 0.5%-10.3%]. On admission, five patients carried CPE (prevalence: 0.69%), 11 ESBL-K. pneumoniae (1.42%), seven CR P. aeruginosa (0.91%) and one CR Acinetobacter spp. (0.14%). The pooled incidence of ICU-acquired colonization during the first two weeks in six out of seven hospitals was 7.42% (19/256) [interhospital range: 0%-27.45%]. CPE colonization was observed in six patients (prevalence: 2.34%), ESBL-K. pneumoniae in one patient (0.39%) and CR P. aeruginosa in 12 (4.68%). Of all detected colonizations, 35 were identified in faecal samples, two in oropharyngeal samples and six in both samples. Finally, sixteen positive cases of infection by these bacteria were detected (pooled prevalence: 2%), nine of them previously colonized by the same microorganism; most of them were CR P. aeruginosa (11/16; 68.7%).

Conclusions: A relatively low prevalence and incidence of the target-ed multidrug-resistant bacteria were observed in the majority of the participant hospitals, although individual hospital variations were detected. CR P. aeruginosa was the most frequent bacteria identified in both colonizations and infections. In this regard, it is strongly advisable to implement the guidelines for infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria. Funding: This research was funded by the Intramural Call for Research Projects CIBERINFEC 2022 (Consortio Centro de Investigación Biomédica en Red, CIBER en Enfermedades Infecciosas).
## 107. GENOMIC CHARACTERIZATION OF KLEBSIELLA PNEUMONIAE ISOLATES BELONGING TO THE ST307 CLONE RECOVERED FROM 45 HOSPITALS IN ANDALUSIA (SPAIN) IN THE PERIOD 2014-2022

Manuel Alcalde-Rico1, Mercedes Delgado-Valverde2, Inés Portillo-Calderón2, Patricia Pérez-Palacios2, Ester Recachá1, Inmaculada López-Hernández2, Felipe Fernández-Cuenca2, Marina R. Pulido1, Álvaro Pascual1,2, Lorena López-Cerero1,2

1Centro de Investigación ‘n Biome’ dica en Red de Enfermedades Infectiosas (CIBERINFE), Instituto de Salud Carlos III, Madrid, Spain. 2UGC Microbiología, Laboratorio de Referencia regional de tipado molecular de patógenos nosocomiales, Hospital Virgen Macarena, Sevilla, Spain. 3Departamento de Microbiología, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain.

**Introduction:** Klebsiella pneumoniae (KPN) is one of the most important opportunistic pathogens worldwide, easily acquires antibiotic resistance genes (ARGs) through horizontal gene transfer and some specific clones (STs) are predominant in specific regions and may cause nosocomial outbreaks. Tracing the emergence and spread of these predominant clones is important to monitor and control multiresistant pathogens.

**Objectives:** To describe the clonal evolution of KPN ST307 isolates collected from 45 hospitals in Andalusia during 2014-2022 and to analyse the genomic characteristics that could be influencing the expansion of ST307 in this region.

**Methods:** 2533 isolates were send from 45 hospitals in Andalusia 2014-2022 to the PIRASOA reference laboratory (Hospital Universitario 12 de Octubre, Madrid, Spain). Initial characterization was performed by PFGE and phenotypic tests following EUCAST recommendations. Whole genome sequencing (WGS) (Illumina Miseq 2x300 bp) of representative isolates of the different pulse types was carried out. Identification of relevant betalactamases was performed by lateral immunochromatography, inhibitors discs, WGS or PCR plus Sanger sequencing. Genomes sequences were de novo assembled with “SPAdes”, annotated with “Bakta” and ARGs were identified with “RESfinder”. The core and accessory genomes were performed with “Roary” and compared to Ridom scheme. The phylogenomic reconstruction was carried out with “RaxML” and “ClonalFrameML”.

**Results:** In the recent years (2018-2022), a clonal shift was observed, in which ST307 emerged as predominant (23.9%) over ST512 and ST15, which were predominant in 2014-2017. ST307 was recovered in which ST307 emerged as predominant (23.9%) over ST512 and ST15. ST307 was recovered from all sample type (clinical, colonization and hospital plumbing). The phylogenomic reconstruction showed a highly conserved core genome (4,360 genes present in 99% of the ST307 sequenced) and an accessory genome with greater diversity among those cgMLSTs disseminated in different hospitals compared to those associated with specific hospitals or regions.

**Conclusions:** Both ST512 and ST15 clones had been progressively displaced by ST307. The ST307 genomes present a great similarity but with a diverse accessory genome that could explain their adaptation to different environments (infection, colonization and humid reservoirs) and, therefore, their expansion in hospital settings. Moreover, more analysis should be carried out to deep into this hypothesis.

Funding: This work has been financed by CIBERINFEKT through a PhD researcher contract (M. Alcalde-Rico).

## 109. GENOMIC CHARACTERIZATION, ANTIMICROBIAL SUSCEPTIBILITY AND VACCINE REACTIVITY TO 4CMENB OF NEISSERIA MENINGITISD PRODUCING INVASIVE MENINGOCOCCAL DISEASE IN SPAIN

Josep Roca-Grande1,2, Alba Mir-Cros1,2, Carmen Ardanuy1,4, Alba Bellés1, Jorge Calvo6, Jordi Cámara1,4, Emilio Cendejas-Bueno1, Emilia Cercedano4,5, Pilar Egea3, Frederic Gómez-Bertomeu6, Luis Martínez-Martínez2, Carmen Muñoz-Almagro4,5, Daniel Navarro de la Cruz2,6, M. Ángeles Orellana13, Amashre Pérez1, María Dolores Quesada14, Carlos Rodrigo1,4, Ana Rodríguez-Fernández2, Enrique Ruiz de Goepgui2,3, Carolina Sarvisé6, Juan José González-López1,2

1Hospital Universitari Vall d’Hebron, Barcelona, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFE), Madrid, Spain. 3Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain. 4Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 5Hospital Universitari Arnau de Vilanova, Lleida, Spain. 6Hospital Universitario Marqués de Valdecilla, Santander, Spain. 7Hospital Universitario La Paz, Madrid, Spain. 8Hospital Universitario Gregorio Marañón, Madrid, Spain. 9Hospital Universitario Reina Sofia, Córdoba, Spain. 10Hospital Universitario Joan XXIII, Tarragona, Spain. 11Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain. 12Hospital Clinic Universitario de Santiago, Santiago de Compostela, Spain. 13Hospital Universitaria 12 de Octubre, Madrid, Spain. 14Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 15Hospital Universitari Son Espases, Palma, Spain.

**Introduction:** Neisseria meningitidis (Nm) is one of the most important pathogens worldwide, easily acquires antibiotic resistance genes (ARGs) through horizontal gene transfer and some specific clones (STs) can be predominant in specific regions and may cause meningococcal disease (IMD). NmW and NmC are the most prevalent lineages in Spain. During the pandemic situation, NmE and NmF have become more prevalent. The objective of this study is to describe the genomic epideimology of IMD-causing Nm in Spain.

**Methods:** A total of 282 Nm producing IMD were studied and collected from various clinical microbiology laboratories in Spain between 2011-2022. Molecular characterization was performed by whole genome sequencing. Serogroups were identified by analyzing the capsular genes and reactivity to 4CMenB was predicted by analysing the vaccine antigenic variants (MenDeVAR index). Antimicrobial susceptibility testing to macrolides, fluoroquinolones, beta-lactams, chloramphenicol, rifampicin and cotrimoxazole was performed by gradient diffusion test.

**Results:** An increase in IMD cases was observed from 2011 to 2019. However, an abrupt decrease was observed during the COVID-19 pandemic in 2020. Serogroup W was the most prevalent (57.4%), followed by W (23.0%), C (10.3%) and Y (7.1%). During the pandemic situation, serogroup W remains the predominant cause of IMD. Genomic epidemiology showed that the most prevalent lineage among NmW was CC-ST213 (35.8%), followed by CC-ST461 (13%), CC-ST269 (12.3%) and CC-ST32 (11.7%). For NmW and NmC, the most prevalent lineage was
Introduction: The incidence of non-AIDS defining cancer is higher in people living with HIV (PLWH) than in the general population, and it is already one of the leading causes of death in the HIV-infected population. Early diagnosis through intensive cancer screening may improve the ability for therapeutic interventions and could be critical in reducing mortality, but it might also increase expenditure and harms associated with adverse events.

Objectives: The aim of this study is to evaluate the efficacy, safety, and efficiency of an enhanced screening program for early diagnosis of cancer in PLWH compared to standard practice.

Methods: A multicenter, non-blinded, randomized, controlled trial comparing two parallel arms: conventional vs enhanced screening. Conventional intervention group has followed the standard of care screening in the participating centers, according to the European-AIDS-Clinical-Society recommendations, and the enhanced intervention group an expanded screening aimed to early detection of lung, liver, anal, cervical, breast, prostate, colorectal, and skin cancer. The primary efficacy analysis will be the comparison of proportion of cancers diagnosed at early stage (1B2) in each group following the principle of intent to screen. A sample size of 1700 patients has been calculated with a follow-up of 6 years. Interim analyses for futility, safety, and efficacy are planned every 12 months.

Results: The recruitment began on 25 June 2019, but unfortunately, it was disrupted by the COVID-19 pandemic. Because of the overall delay in recruitment, the study duration has been extended. 1,164 patients have already been recruited with a follow-up of 22 (10-35) months. In the interim analysis, no safety concerns were raised and the trial is ongoing. So far, 10 carcinomas and 35 premalignant neoplastic lesions have been detected. Distribution of carcinomas is as follows: hepatocellular carcinoma, 2 cases (enhanced: 1, conventional: 1); colorectal adenocarcinoma 1 case (enhanced: 1); lung cancer 2 cases (enhanced: 1, conventional: 1); cervical cancer 1 case (enhanced: 1), and skin basal cell carcinoma, 3 cases, all of them in the enhanced screening-arm. Among premalignant lesions, most cases are anal and cervical high-grade squamous intraepithelial lesions (enhanced: 13; conventional-screening: 10 cases) and colorectal adenocarcinoma precursors lesions (enhanced: 5; conventional-screening: 8 cases). We will present the updated results in the meeting.

Conclusions: This multicenter pragmatic trial will help to determine whether the benefits of an enhanced cancer screening outweigh the harms in PLWH and if it is cost-effective for the Public Health Services. The information provided will be relevant since there are currently no studies on expanded cancer screening strategies in PLWH. Funding: This project has been financed by the ISCIII (P18/01861) and supported by CIBER (CB21/13/0001), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU.
Methods: KPC-KP colonized patients were recruited in a tertiary hospital with endemicity by a ST512/KPC-3 K. pneumoniae clone. Rectal swabs were collected at recruitment and monthly thereafter for one year. The RLKPC was estimated by qPCR and defined as the proportion of blaKPC relative to 16S rRNA gene copy number. Sustained eradication was defined as the absence of KPC-KP both by culture and qPCR and no subsequent positive swabs during follow-up. Factors associated with sustained eradication were evaluated by a Fine-Gray analysis, establishing death as competing risk. Whole-Genome Sequencing (WGS) (Illumina) was performed to study the clonality between KPC-KP colonizing and infection isolates.

Results: Among 80 patients recruited, 68 (85.0%) were hospitalized. Carriage of KPC-KP was confirmed in 89.6% (43/48), 71% (27/38), 41.4% (12/29) and 33.3% (7/21) patients with available follow-up samples at 1, 3, 6, and 12 months, respectively. The median RLKPC was 0.28% (range 0.001%-2.70%, minimum < 0.001, maximum 59.39%) at baseline, 0.02% (range < 0.001%-0.41%, p-value relative to baseline = 0.055) at 1 month and remained below 0.001% (p < 0.001) thereafter. Twenty-four (27.5%) patients had at least one rectal swab sample negative for KPC-KP during follow-up, however only 15 (18.8%) showed sustained eradication, within a median time of 90 days (range 75-120). During follow-up, 43 (53.8%) patients died and 33 (41.3%) developed KPC-KP-related infections. In multivariable analysis, Charlson Comorbidity Index (SHR 0.473, 95%CI 0.23-0.97, p = 0.041) was independently associated with sustained eradication were evaluated by a Fine-Gray analysis, establishing death as competing risk. Whole-Genome Sequencing (WGS) (Illumina) was performed to study the clonality between KPC-KP colonizing and clinical isolates, all belonging to the ST512/KPC-3 KP clone.

Conclusions: The RLKPC is not associated with sustained eradication of KPC-KP in colonized patients. A high Charlson comorbidity index is associated with lower probability of sustained eradication. This is important to implement adequate preventive measures.

Funding: This work was supported by (i) Plan Estatal de I+D+I 2013-2016, cofinanced by the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación and FEDER (FIS PI16/01631 granted to E.P.N.); (ii) Plan Nacional de I+D+I 2013-2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, and cofinanced by the European Development Regional Fund “A Way to Achieve Europe” Operative Program Smart Growth 2014-2020, (RIEPI) (RD16/0016/0008); and (iii) Consejería de Salud y Familias, Junta de Andalucía (RH-0065-2020 granted to E.P.N.).

120. NOVEL CYCLIC PEPTIDES AS EFFLUX PUMP INHIBITORS: AN INTERESTING APPROACH AGAINST MULTIDRUG-RESISTANT P. AERUGINOSA

Natalia Rosón-Calero1, Clara Ballesté-Delpierre1, Jordi Vila Estapé1,2
1ISGlobal, Barcelona, Spain. 2Hospital Clinic Barcelona, Barcelona, Spain.

Introduction: The spread of multidrug resistant (MDR) Gram-negative pathogens is a global health threat. Among the mechanisms that drive resistance in MDR pathogens, overexpression of multidrug efflux pumps is one of the most prevalent. The lack of development of new antimicrobials effective against MDR pathogens makes efflux pumps inhibitors (EPIs), like the well-studied Phenylalanine-arginine-β-naphthylamide (PAβN), a promising new strategy to restore antimicrobial susceptibility.

Objectives: The objective of this study was to analyse the antimicrobial susceptibility profile of two novel synthetic cyclic peptides (CPs): CP1 and CP3 against a collection of Pseudomonas aeruginosa presenting different genetic backgrounds.

Methods: After phenotypic characterization of the efflux pump overexpression and checking that CPs do not inhibit cell growth, Minimum Inhibitory Concentrations (MIC) of tetracycline (TET), minocycline (MINO), tigecycline (TIGE), aztreonam, cefepime, meropenem, imipenem, chloramphenicol and netilmicin were determined using broth microdilution assay. Ten P. aeruginosa strains presenting different RND-efflux pump expression profiles were selected for the study. The assays were performed in the presence of a constant concentration of 100 μg/mL of PAβN and CPs to compare their activity.

Results: Among the antibiotics screened, tetracycline (TET) and minocycline (MINO) showed activity combined with CP1 and CP3, and tigecycline (TIGE) in combination with CP1 (CP3 currently being tested) as seen in the Table. Chloramphenicol showed synergistic activity only when combined with CP1 in strains 125A and 125B reducing the MIC by 3 and 4-folds, respectively (MIC = 8 μg/mL in the presence of CP1). In the case of netilmicin, only CP3 showed a reduction in the MIC to up to 3-folds for most of the strains tested, except for three.

Conclusions: These preliminary results suggest that CP1 and CP3 have potential auxiliary activity in vitro when combined with different antibiotics, particularly for tetracycline-related antibiotics. Susceptibility to tetracycline and its derivatives minocycline and tigecycline, in the case of CP1, is higher in combination of the CPs tested. Further studies regarding the characterization of the compounds are being performed to disclose how the active compounds found in our study act as EPIs.

Funding: This study is part of the intramural CIBERInfec project IM22/INF/4.

121. FUNCTIONAL AND GENOMIC ANALYSIS OF LEISHMANIA CLINICAL ISOLATES: PROMOTING GENOMIC PERSONALIZED MEDICINE IN LEISHMANIASIS

Jose Carlos Solana1,2, Lorena Bernardo1,2, Sandra González-de-la-Fuente1, Carmen Chicharro1,4, Emilia García1, Eugenia Carrillo1,2, Begona Aguado1, Juan Víctor San Martín1,4, Begona Monge1,2, Jose María Requena1,2, Javier Moreno1,2
1WHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), Instituto de Salud Carlos III, Madrid, Spain. 3Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Genomic and NGS

<table>
<thead>
<tr>
<th>Compound</th>
<th>TET</th>
<th>TET + CP1</th>
<th>Fold change</th>
<th>TET + CP3</th>
<th>Fold change</th>
<th>MINO</th>
<th>MINO + CP1</th>
<th>Fold change</th>
<th>MINO + CP3</th>
<th>Fold change</th>
<th>TIGE</th>
<th>TIGE + CP1</th>
<th>Fold change</th>
</tr>
</thead>
<tbody>
<tr>
<td>41A</td>
<td>16</td>
<td>8</td>
<td>1</td>
<td>16</td>
<td>-</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>41B*</td>
<td>16</td>
<td>8</td>
<td>1</td>
<td>16</td>
<td>-</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>125A</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>-</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>125B*</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>-</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>PAO1 (wt)</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>-</td>
<td>8</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>PAOM*</td>
<td>1</td>
<td>0,5</td>
<td>1</td>
<td>0,06</td>
<td>4</td>
<td>2</td>
<td>0,5</td>
<td>2</td>
<td>0,5</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PAOMRx*</td>
<td>16</td>
<td>4</td>
<td>2</td>
<td>8</td>
<td>1</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>PAOW (wt)</td>
<td>16</td>
<td>2</td>
<td>3</td>
<td>8</td>
<td>1</td>
<td>16</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>PAOW*</td>
<td>16</td>
<td>4</td>
<td>2</td>
<td>32</td>
<td>1</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>PAO ΔmesZ</td>
<td>16</td>
<td>2</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>16</td>
<td>2</td>
</tr>
</tbody>
</table>

*41B: overexpr. mexY, ΔoprD; 125B: overexpr. mexB; PAOM*: ΔoprM; PAOMRx*: def mexR; PAOW: ΔoprF; PAO1: ΔmesZ. Results are expressed in μg/mL.
Introduction: Leishmaniasis is the second most important parasitic disease after malaria, and the ninth most significant infectious disease worldwide. Treatment consists on a very limited number of antiparasitic drugs. The extraordinary genomic plasticity of *Leishmania* parasite leads to the appearance of drug resistance, associated with treatment failure and selection of multiresistant strains, especially in immunosuppressed individuals.

Objectives: This work aims to achieve a genetic and phenotypic characterization of *Leishmania* clinical isolates to evaluate the pathogenic features of the strains and find individualized and appropriate treatments.

Methods: Cell viability was measured using resazurin in *Leishmania* strains isolated from patients of Spanish hospitals and the collaborators of the WHO Collaborating Centre for Leishmaniasis when challenged with leishmanicidal drugs: amphotericin B, antimonials, miltefosin and paromomycin. On the other hand, DNA from clinical strains was isolated for its whole genome sequencing. The reads were aligned with the *Leishmania* reference genome and gene copy number variation was examined, besides ploidy and somy analyses. Moreover, maxicircle DNA of each strain was assembled for genotyping.

Results: The phylogenetic study of *Leishmania* strains has revealed the existence of at least two populations of the parasite circulating in Spain in different evolutionary stages, probably related with the inclusion of new reservoirs in the last leishmaniasis outbreak in Madrid, the most important in Europe. It has been also observed differences in resistance and susceptibility profiles to drug treatment, regarding EC50 values of each drug. The suitability of these analyses has been demonstrated in collaboration with Begoña Monge, from Jose Antonio Pérez Molina’s CIBER group, in clinical isolates from patients suffering continuous relapses and receiving different treatments. A genetic profile of resistance to some of those has been found, including gene mutations related with the resistant phenotype.

Conclusions: The combination of genomic and phenotypic studies of *Leishmania* clinical isolates has been demonstrated to be useful for genotyping and determining the virulence and drug resistance profile, enabling to select an appropriate treatment, preventing therapeutic failures and emergence of resistances. In light of this research, future collaborations will be prompted with more CIBER groups specialized in leishmaniasis and bioinformatic analyses, in order to perform this kind of analysis in collaboration with Spanish hospitals in the framework of genomic and personalized medicine. This would undoubtedly result in a substantial improvement in the health and wellness of patients, reducing the cost of treatment and disease burden.

Funding: CB21/13/00018, LeishAccess (EDCTP-RIA2020S-3301), CB21/13/00085.